Associate Professor Anthony Joshua

Back to

Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto, Canada to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis, and a clinical Fellowship under Dr Ian Tannock.

He joined the Department of Medical Oncology at Princess Margaret Cancer Centre in Toronto as a staff oncologist in late 2008, specialising in genito-urinary malignancy and melanoma with research interests in circulating tumour DNA, tumour heterogeneity, mechanisms of enzalutamide resistance and autophagy.

He returned to Australia, joining the Kinghorn Cancer Centre and the Garvan Institute of Medical Research in late 2015. He is currently a conjoint Associate Professor with the University of New South Wales.

Phone

0293555655

E-mail

anthony.joshua@svha.org.au

Book Chapters | 2020

Covelli AM; Joshua AM; Lipa JE; Butler MO; Snell L; Sun A; Wright FC, 2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 333 - 343,

Book Chapters | 2020

Lim DW; Yin L; Racz JM; Joshua AM; Abadir WWK; Butler MO; Lipa JE; Sun A; Wright FC, 2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 383 - 393,

Book Chapters | 2016

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196,

Book Chapters | 2016

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232,
Journal articles | 2024

Azad A; Voskoboynik M; Joshua AM; Weickhardt AJ; Sankey P; Pacey S; Heath EI; Krieger L; Horvath L; Pilié PG; Womersley L; Linardopoulos S; Moorthy G; Zhou TJ; Brown J; de Paula B; Lukacs E; Hudson A, 2024, 'PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.', Journal of Clinical Oncology, 42, pp. 123 - 123,

Journal articles | 2024

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276,

Journal articles | 2024

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67,

Journal articles | 2024

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571,

Journal articles | 2024

Fleshner NE; Bernardino RM; Lajkosz K; Saad F; Izawa J; Drachenberg D; Saranchuk JW; Tanguay S; Rendon RA; Leveridge M; Shayegan B; Fairey A; Cockburn JG; Berlin D; Hamilton RJ; Sildva T; Breau RH; Richard PO; Klotz L; Joshua AM, 2024, 'A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.', Journal of Clinical Oncology, 42, pp. LBA5002 - LBA5002,

Journal articles | 2024

Hall A; Crumbaker M; Pham J; Liu JJ; Sim H-W; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', Journal of Clinical Oncology, 42, pp. 4 - 4,

Journal articles | 2024

Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M, 2024, 'Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma', Ophthalmology Retina, 8, pp. 325 - 330,

Journal articles | 2024

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107,

Journal articles | 2024

Horvath LG; Lin H-M; Davis ID; Martin A; Scheinberg T; Meikle P; Joshua A; Mcjannett M; Subhash V; Yip S; North S; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', Annals of Oncology, 35, pp. S969 - S970,

Journal articles | 2024

Joshua AM; O'day R; Glasson W; Sia D; McGrath L; Ameratunga M; Cosman R; Cherepanoff S; O'Quigley M; Beaupre DM; Conway M; Lim L-A; McKenzie J; McKay D; Shackleton MJ; Fung A; Isaacs T; Yousif J; Brooks C; Psaroulis T, 2024, 'A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.', Journal of Clinical Oncology, 42, pp. 9510 - 9510,

Journal articles | 2024

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of ⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on ⁶⁸Ga-PSMA-11 PET/CT', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65, pp. 1371 - 1375,

Journal articles | 2024

Lim JWY; Chin VT; Keith P; McCloy R; Neavin D; Xue A; Kaczorowski D; Spenceley E; Arora H; Joshua AM; Powell J, 2024, 'Predicting immunotherapy toxicity through single-cell sequencing of peripheral immune cells: A pilot study.', Journal of Clinical Oncology, 42, pp. e14538 - e14538,

Journal articles | 2024

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014,

Journal articles | 2024

Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM, 2024, 'What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life', Melanoma Research, 34, pp. 248 - 257,

Journal articles | 2024

O'Day RF; Conway RM; Lim LA; Giblin M; Cherepanoff S; Joshua A; McKay D; McKenzie JD; Fog LS; Holly P; Shackleton M; Kee D; Philips C; McKelvie P; Bhikoo R; Hadden P; Negretti GS; Sagoo MS; Damato BE; Sia D; McGrath L; Glasson W; Isaacs T; Gillies M; Barthelmes D, 2024, 'The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma', Canadian Journal of Ophthalmology, 59, pp. e525 - e533,

Journal articles | 2024

Pinato DJ; Jones RH; Forster MD; Joshua AM; Korolewicz J; Benafif S; Aboud K; Liu JJ; Cosman R; Paull J; Fairley J; Edmondson SR; Spicer JF, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 374 - 374,

Journal articles | 2024

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu JJ; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004,

Journal articles | 2024

Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF, 2024, 'Retraction Note: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy (British Journal of Cancer, (2015), 112, 5, (832-840), 10.1038/bjc.2015.17)', British Journal of Cancer, 130, pp. 1232,

Journal articles | 2024

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, 94, pp. 485 - 486,

Journal articles | 2024

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', npj Precision Oncology, 8,

Journal articles | 2024

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976,

Journal articles | 2024

Wahab S; Joshua A; Dhillon HM; Barnet M, 2024, 'Psychological impact of exceptional response in people with advanced cancer: a qualitative exploration', Journal of Cancer Survivorship,

Journal articles | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau HT; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; de Spéville BD, 2024, 'First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study', Cancer Research Communications, 4, pp. 1609 - 1619,

Journal articles | 2024

Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS, 2024, 'Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.', Eur Urol Oncol,

Journal articles | 2024

Yu EY; Joshua AM; Kramer G; Shore ND; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.', Journal of Clinical Oncology, 42, pp. TPS249 - TPS249,

Journal articles | 2024

Yu EY; Joshua AM; Shore ND; Kramer G; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.', Journal of Clinical Oncology, 42, pp. TPS250 - TPS250,

Journal articles | 2024

Zhang J; Joshua AM; Li Y; O'Meara CH; Morris MJ; Khachigian LM, 2024, 'Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma', Cancer Letters, 586,

Journal articles | 2023

Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM, 2023, 'Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.', Eur Urol,

Journal articles | 2023

Azad A; Voskoboynik M; Palma dos Reis AF; Joshua AM; Weickhardt AJ; Jones RJ; Rescigno P; Tran B; Kennedy C; Linardopoulos S; Moorthy G; Zhou TJ; Brown JS; Lukacs E; Francis R; Hudson A, 2023, 'Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).', Journal of Clinical Oncology, 41, pp. TPS296 - TPS296,

Journal articles | 2023

Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S, 2023, 'Advances in the clinical management of uveal melanoma', Nature Reviews Clinical Oncology, 20, pp. 99 - 115,

Journal articles | 2023

Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira De Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S; Alvarez M; Gatica G; Greco M; Korbenfeld E; Metrebian E; Salinas J; Salvatierra A; Tatangelo M; Ferguson T; Gurney H; Hovey E; Joshua A; Marco M; Marx G; Morris M; Ng S; Pook D; Sandhu S; Tafreshi A; Tan TH; Tosheva T; Andrade L; Cruz F; Faria L; Figueiredo J; Franke F; Gomes AJ; Kann A; Kussumoto C; Martins S; Murad A; Pinczowski H; Pioner G; Pires L; Preto D; Santos G; Silva E; Silva J; Viana L; Vianna K; Paula A; Chen Z; Emmenegger U; Fleshner N; Parimi S; Saad F; Vera-Badillo F; Guo H; Luo H; Ma L; Qui M; Xue W; Yonglian G; Li L; Pu J; Zheng S; Zou Q; Brodak M; Hora M; Samal V; Student V; Vanasek J; Bompas E; Barthelemy P; Borchiellini D; Flechon A; Mahammedi H; Thiery-Vuillemin A; Tosi D; Dominique S; Helissey C; Boegemann M; Feyerabend S; Hellmis E; Schostak M; Lydon A; Sayers I; Parikh O, 2023, 'Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer', Journal of Clinical Oncology, 41, pp. 3339 - 3351,

Journal articles | 2023

Choi WWY; Sánchez C; Li JJ; Dinarvand M; Adomat H; Ghaffari M; Khoja L; Vafaee F; Joshua AM; Chi KN; Guns EST; Hosseini-Beheshti E, 2023, 'Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4701 - 4717,

Journal articles | 2023

Conway JRW; Warren SC; Lee YK; McCulloch AT; Magenau A; Lee V; Metcalf XL; Stoehr J; Haigh K; Abdulkhalek L; Guaman CS; Reed DA; Murphy KJ; Pereira BA; Mélénec P; Chambers C; Latham SL; Lenthall H; Deenick EK; Ma Y; Phan T; Lim E; Joshua AM; Walters S; Grey ST; Shi YC; Zhang L; Herzog H; Croucher DR; Philp A; Scheele CLGJ; Herrmann D; Sansom OJ; Morton JP; Papa A; Haigh JJ; Nobis M; Timpson P, 2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9,

Journal articles | 2023

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36,

Journal articles | 2023

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15,

Journal articles | 2023

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. S1325 - S1325,

Journal articles | 2023

Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM, 2023, 'Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial', Clinical Cancer Research, 29, pp. 3867 - 3874,

Journal articles | 2023

Gedye C; Harris CA; Stockler MR; Morris M; Ferguson T; Goh JCH; Martin A; Underhill CR; Pook D; Krieger LEM; Kichenadasse G; Joshi AJ; Subramaniam S; Zebic DS; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Davis ID, 2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. S1014 - S1014,

Journal articles | 2023

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; PASAM A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989,

Journal articles | 2023

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256,

Journal articles | 2023

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064,

Journal articles | 2023

Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P, 2023, 'Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma', New England Journal of Medicine, 389, pp. 2256 - 2266,

Journal articles | 2023

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer.', Journal of Clinical Oncology, 41, pp. e17009 - e17009,

Journal articles | 2023

Horvath LG; Kench C; Mellor R; Lin H-M; Mak B; Scheinberg T; Mahon K; Graham L; Azad AA; Joshua AM; Stockler MR; Marx GM; Briscoe K; Samaras K, 2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. S991 - S991,

Journal articles | 2023

Inderjeeth AJ; Hurwitz J; Joshua AM; Kee D, 2023, 'Real-world experience of tebentafusp for uveal melanoma via an Australian access program.', Journal of Clinical Oncology, 41, pp. e21554 - e21554,

Journal articles | 2023

Jamal S; Nagrial A; Carlino M; Cosman R; Joshua A; Eek R; Piha-Paul S; Hamid O; Liu J, 2023, 'Abstract CT267: ENB-003, an ETBR antagonist, in combination with pembrolizumab for advanced solid tumor: The ENBolden trial', Cancer Research, 83, pp. CT267 - CT267,

Journal articles | 2023

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415,

Journal articles | 2023

Lin FP-Y; Joshua AM; Epstein RJ, 2023, 'Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.', Journal of Clinical Oncology, 41, pp. e13564 - e13564,

Journal articles | 2023

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Gaus A; Yau W; Cosman R; Chwialkowska D; Paull JRA; Jean-Francois BM; Fairley JK; Main NJ; Edmondson SR; Cook N, 2023, 'Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours', Molecular Cancer Therapeutics, 22, pp. B039 - B039,

Journal articles | 2023

O'day R; Conway M; Lim L-A; McKenzie J; Atkinson V; Glasson W; McGrath L; Cherepanoff S; Gray E; Maurer MA; O'Quigley M; Shackleton MJ; Joshua AM, 2023, 'NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).', Journal of Clinical Oncology, 41, pp. TPS9612 - TPS9612,

Journal articles | 2023

Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y; Greco MA; Coward J; Joshua A; Karapetis C; Hart C; Zhang A; Prenen H; Goeminne JC; Machiels JP; Rottey S; Corassa M; Molin GZD; Tiscoski K; Jardim DLF; Mak M; Fu W; Yao H; Huang J; Jiang H; Chen B; Yan D; Yang Y; Le Tourneau C; Penel N; Salas S; Blay JY; Brachet PE; Durando X; Emambux S; Ravaud A; Folprecht G; Ahrens M; Golf A; Haag GM; Lordick F; Desuki A; Cazzaniga M; Ciardiello F; Milella M; Koyama T; Hirooka Y; Okamoto W; Aogi K; Kuboki Y; Lee J; Kim SB; Ahn MJ; Chang JH; Kim YM; Nam DH; Park JS; Paz-Ares L; Moreno V; Cervantes A; Calvo M; Falcon A; Gonzalez A; Martinez Bueno A; García-Corbacho J; Longo F; Yen CJ; Chen JS; Hou MF; Chao Y; Rau KM; Chiu TJ; Feng YH; Hsu CH; Huang WT; Lai KM; Yeh SP; Palmer D; Welsh L; Plummer R; Iyer G; Bilen M, 2023, 'Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study', The Lancet Oncology, 24, pp. 925 - 935,

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226,

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74,

Journal articles | 2023

Pham JP; Hurwitz J; Cosman R; Goldinger SM; Sim H-W; Dummer R; Joshua AM, 2023, '1127P Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis', Annals of Oncology, 34, pp. S677 - S677,

Journal articles | 2023

Pham JP; Joshua AM; da Silva IP; Dummer R; Goldinger SM, 2023, 'Chemotherapy in Cutaneous Melanoma: Is There Still a Role?', Current Oncology Reports, 25, pp. 609 - 621,

Journal articles | 2023

Pham JP; On L; Ardolino L; Hurwitz J; Salaun H; Sim HW; Joshua AM, 2023, 'Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis', Melanoma Research, 33, pp. 316 - 325,

Journal articles | 2023

Piperno-Neumann S; Hassel JC; Rutkowski P; Baurain J-F; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Carvajal RD; Hamid O; Collins L; Holland C; Nathan P, 2023, 'LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial', Annals of Oncology, 34, pp. S1289 - S1290,

Journal articles | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H, 2023, 'A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer', Clinical Cancer Research, 29, pp. 3292 - 3300,

Journal articles | 2023

Rodrigues A; Cosman R; Joshua AM, 2023, 'Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress (British Journal of Cancer, (2023), 128, 10, (1791-1793), 10.1038/s41416-023-02199-w)', British Journal of Cancer, 128, pp. 1976,

Journal articles | 2023

Rodrigues A; Cosman R; Joshua AM, 2023, 'LXS196 for Metastatic Uveal Melanoma - finally some progress', British Journal of Cancer, 128, pp. 1791 - 1793,

Journal articles | 2023

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005,

Journal articles | 2023

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Lee ST; Weickhardt AJ; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271,

Journal articles | 2023

Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Ståhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K, 2023, 'Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects', Journal of Managed Care and Specialty Pharmacy, 29, pp. 758 - 768,

Journal articles | 2023

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Cheung L; Chi KN; Chowdhury S; Frydenberg M; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter D; Yip S; Zhang AY; Zielinski RR; Davis ID; Abdi E; Allan S; Bastick P; Blum R; Briscoe K; Brungs D; Bydder S; Chittajallu BR; Cronk M; Cuff K; Dowling A; George M; Horvath L; Hovey E; Karanth N; Kichenadasse G; Krieger L; Mathlum M; Nott L; Otty Z; Sewak S; Stevanovic A; Suder A; Tan H; Torres J; Troon S; Underhill C; Weickhardt A; Abbas T; Anan G; Booth C; Campbell H; Chin J; Chouinard E; Donnelly B; Drachenberg D; Faghih A; Finelli A; Hotte S; Noonan K; Rassouli M; Reaume N; Rendon R; Saad F; Sadikov E; Vigneault E; Zalewski P; Morris P; O'Connor M; Donnellan P; O'Donnell D; Edwards J; Fong P; Crabb S; Khan O; Khoo V; Macdonald G; Payne H; Robinson A; Shamash J; Staffurth J; Thomas C, 2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334,

Journal articles | 2023

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485,

Journal articles | 2023

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127,

Journal articles | 2023

Wong D; Luo P; Znassi N; Arteaga DP; Gray D; Danesh A; Han M; Zhao EY; Pedersen S; Prokopec S; Sundaravadanam Y; Torti D; Marsh K; Keshavarzi S; Xu W; Krema H; Joshua AM; Butler MO; Pugh TJ, 2023, 'Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma', Cancer Research Communications, 3, pp. 267 - 280,

Journal articles | 2022

Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ, 2022, 'Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: Interim results from a multicenter phase I/II trial', Journal for ImmunoTherapy of Cancer, 10,

Journal articles | 2022

Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM, 2022, 'Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future', Annals of Oncology, 33, pp. 574 - 577,

Journal articles | 2022

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS; Akhurst T; Alipour R; Banks P; Beaulieu A; Chua W; Dhiantravan N; Ford K; Gedye C; Goh JC; Guminski A; Hamid A; Haskali MB; Hicks RJ; Hsiao E; Kirkwood ID; Kong G; Kwan EM; Langford A; Lawrence N; Lewin J; Lin P; McDonald W; Moodie K; Murphy DG; Ng S; Pattison DA; Pokorski I; Ramdave S; Ravi Kumar AS; Redfern AD; Rutherford NK; Saghebi J; Spain L; Subramaniam S; Tan TH; Thang SP; Tran B; Wallace R; Weickhardt A; Yip S, 2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397,

Journal articles | 2022

Chen S; Petricca J; Ye W; Guan J; Zeng Y; Cheng N; Gong L; Shen SY; Hua JT; Crumbaker M; Fraser M; Liu S; Bratman SV; van der Kwast T; Pugh T; Joshua AM; De Carvalho DD; Chi KN; Awadalla P; Ji G; Feng F; Wyatt AW; He HH, 2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13,

Journal articles | 2022

Chin V; Arora H; Senabouth A; Hernandez JA; McCloy R; Simes J; Boyer M; Hogg P; Young J; Joshua A; Brown B; Watkins N; Powell J, 2022, 'EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers', Journal of Thoracic Oncology, 17, pp. S608 - S608,

Journal articles | 2022

Jones RH; Pinato DJ; Joshua A; Forster MD; Morton C; Aboud K; Liu JJ; Fulgenzi C; Kefas J; Edmondson S; Main NJ; Paull JRA; Fairley JK; Spicer J, 2022, '1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial', Annals of Oncology, 33, pp. S1186 - S1187,

Journal articles | 2022

Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM, 2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295,

Journal articles | 2022

Joshua AM; Gurney H; Dhillon HM; Crumbaker M, 2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242,

Journal articles | 2022

Linch M; Ferrario C; Stoeckle M; Laguerre B; Arranz Arija JA; Todenhöfer T; Fong PC; Piulats Rodriguez JM; Berry W; Emmenegger U; Mourey L; Mar N; Appleman LJ; Joshua A; Conter HJ; Li XT; Schloss C; Poehlein CH; de Bono JS; Yu EY, 2022, '1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)', Annals of Oncology, 33, pp. S1178 - S1178,

Journal articles | 2022

Maio M; Carlino MS; Joshua AM; McWhirter E; Ribas A; Ascierto PA; Miller WH; Butler MO; Ferrucci PF; Zielinski RR; Del Vecchio M; Gasal E; Ghori R; Diede SJ; Croydon E; Hamid O, 2022, 'KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation', European Journal of Cancer, 160, pp. 1 - 11,

Journal articles | 2022

Mak B; Lin HM; Duong T; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang A; Scheinberg T; Wittert G; Butler LM; Sullivan D; Hoy AJ; Meikle PJ; Horvath LG, 2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14,

Journal articles | 2022

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20,

Journal articles | 2022

Marastoni S; Madariaga A; Pesic A; Nair SN; Li ZJ; Shalev Z; Ketela T; Colombo I; Mandilaras V; Cabanero M; Bruce JP; Li X; Garg S; Wang L; Chen EX; Gill S; Dhani NC; Zhang W; Pintilie M; Bowering V; Koritzinsky M; Rottapel R; Wouters BG; Oza AM; Joshua AM; Lheureux S, 2022, 'Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer', Cancer Research Communications, 2, pp. 293 - 306,

Journal articles | 2022

Nguyen LT; Lo CS; Fyrsta M; Nie J; Yam JY; Yen PH; Le MX; Hersey K; Kenk M; Crumbaker M; Fleshner N; Kulkarni G; Hamilton R; Jewett M; Finelli A; Evans A; Sweet J; Ohashi PS; Joshua AM, 2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022,

Journal articles | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566,

Journal articles | 2022

Peter MR; Bilenky M; Shi Y; Pu J; Kamdar S; Hansen AR; Fleshner NE; Sridhar SS; Joshua AM; Hirst M; Xu W; Bapat B, 2022, 'A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer', Epigenomics, 14, pp. 811 - 822,

Journal articles | 2022

Pham JP; Star P; Ardolino L; Smith A; Joshua AM, 2022, 'A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions', Australasian Journal of Dermatology, 63, pp. e279 - e282,

Journal articles | 2022

Pham JP; Star P; Phan K; Loh Y; Joshua AM; Smith A, 2022, 'BRAF inhibition and the spectrum of granulomatous reactions', Journal of the American Academy of Dermatology, 87, pp. 605 - 613,

Journal articles | 2022

Schlaak M; Dummer R; Kirkwood JM; Joshua A; Milhem M; Gastaud L; Mauch C; Yushak ML; Lockwood S; Hayes C; Shoushtari AN, 2022, '821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma', Annals of Oncology, 33, pp. S923 - S923,

Journal articles | 2022

Smith MR; Scher HI; Sandhu S; Efstathiou E; Lara PN; Yu EY; George DJ; Chi KN; Saad F; Ståhl O; Olmos D; Danila DC; Mason GE; Espina BM; Zhao X; Urtishak KA; Francis P; Lopez-Gitlitz A; Fizazi K; Parnis F; Joshua AM; Horvath LG; Steer C; Marx G; Gurney H; Ferguson T; Van Bruwaene S; Luyten D; Schatteman P; Lumen N; Dirix L; Goeminne JC; Gil T; Seront E; Vulsteke C; Kussumoto C; Franke FA; Martinelli de Oliveira FA; Pereira de Santana Gomes AJ; Pinczowski H; Preto DDA; Zucca LE; Borges GS; Murad AM; Fradet Y; Fleshner NE; Emmenegger U; Brasso K; Culine S; Thiery-Vuillemin A; Joly F; Fléchon A; Hilgers W; Eymard JC; Borchiellini D; Barthélémy P; Berger R; Leibowitz-Amit R; Mermershtain W; Rouvinov K; Peer A; Kovel S; Sella A; Lolkema MP; van den Eertwegh AJM; Voortman J; Aarts MJ; Gietema JA; Kim CS; Choi YD; Chung BH; Gafanov RA; Kopyltsov E; Usynin EA; Carles J; Mellado B; Maroto JP; García-Donás J; Rodríguez Moreno JF; Durán I; Pérez-Valderrama B; Castro E; Méndez-Vidal MJ; Estellés DL; Sarrió RG; Muñoz-Langa J; Herranz UA; Puente Vázquez J; Castellanos E; Hellström M; Widmark A; Lissbrant IF; Jellvert Å; Külich C; Blom R; Chiang PH; Kang CH; Ou YC; Wang SS; Wu HC, 2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 362 - 373,

Journal articles | 2022

Stockler MR; Martin AJ; Davis ID; Dhillon HM; Begbie SD; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar WR; Pook DW; Reaume MN; Sandhu S; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter DG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ, 2022, 'Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP', Journal of Clinical Oncology, 40, pp. 837 - 846,

Journal articles | 2022

Tannock IF; Booth CM; Gyawali B; Joshua AM, 2022, 'Radiographic progression-free survival in the ACIS trial for prostate cancer', The Lancet Oncology, 23, pp. e4,

Journal articles | 2022

Wilson BE; Armstrong AJ; de Bono J; Sternberg CN; Ryan CJ; Scher HI; Smith MR; Rathkopf D; Logothetis CJ; Chi KN; Jones RJ; Saad F; De Porre P; Tran NP; Hu P; Gillessen S; Carles J; Fizazi K; Joshua AM, 2022, 'Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302', European Journal of Cancer, 170, pp. 296 - 304,

Journal articles | 2022

Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS, 2022, 'Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study', European Urology, 82, pp. 22 - 30,

Journal articles | 2021

Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U, 2021, 'Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 with Cognitive Function in Older Men with Metastatic Castration-Resistant Prostate Cancer', JAMA Network Open, 4,

Journal articles | 2021

Alibhai SMH; Breunis H; Hansen AR; Gregg R; Warde P; Timilshina N; Tomlinson G; Joshua AM; Hotte S; Fleshner N; Emmenegger U, 2021, 'Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor–targeted therapy for metastatic castration-resistant prostate cancer', Cancer, 127, pp. 2587 - 2594,

Journal articles | 2021

Appleman LJ; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Romano E; Gravis G; Gurney H; De Bono JS; Boegemann M; Emmenegger U; Joshua AM; Massard C; Sridhar SS; Conter HJ; Li XT; Schloss C; Poehlein CH; Yu EY, 2021, 'KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.', Journal of Clinical Oncology, 39, pp. 10 - 10,

Journal articles | 2021

Bono JD; Shore N; Kramer G; Joshua A; Li XT; Poehlein C; Schloss C; Yu E, 2021, '418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma', Regular and Young Investigator Award Abstracts, pp. A448 - A448,

Journal articles | 2021

Chan WY; Brown LJ; Reid L; Joshua AM, 2021, 'Parp inhibitors in melanoma—an expanding therapeutic option?', Cancers, 13,

Journal articles | 2021

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970,

Journal articles | 2021

Dhiantravan N; Emmett L; Joshua AM; Pattison DA; Francis RJ; Williams S; Sandhu S; Davis ID; Vela I; Neha N; Bressel M; Murphy DG; Hofman MS; Azad AA, 2021, 'UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342,

Journal articles | 2021

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651,

Journal articles | 2021

Eskander A; Marqueen KE; Edwards HA; Joshua AM; Petrella TM; de Almeida JR; Goldstein DP; Ferket BS, 2021, 'To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma', Cancer, 127, pp. 2333 - 2341,

Journal articles | 2021

Gedye C; Joshi AJ; Zhang AY; Martin AJ; Joshua AM; Harris CA; Underhill C; Pook DW; Toner GC; Kichenadasse G; So JY; Goh JC; Morris MF; Lawrence NJ; Ferguson T; Vasey PA; Prithviraj P; Subramaniam S; Stockler MR; Davis ID, 2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', JOURNAL OF CLINICAL ONCOLOGY, 39,

Journal articles | 2021

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Link E; Davis ID, 2021, 'Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, 39,

Journal articles | 2021

Hamid O; Robert C; Daud A; Carlino MS; Mitchell TC; Hersey P; Schachter J; Long GV; Hodi FS; Wolchok JD; Arance A; Grob JJ; Joshua AM; Weber JS; Mortier L; Jensen E; Diede SJ; Moreno BH; Ribas A, 2021, 'Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006', European Journal of Cancer, 157, pp. 391 - 402,

Journal articles | 2021

Hassel JC; Rutkowski P; Baurain J-F; Butler MO; Schlaak M; Sullivan R; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Nathan P; Piperno-Neumann S, 2021, 'Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.', JOURNAL OF CLINICAL ONCOLOGY, 39,

Journal articles | 2021

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID; Dhiantravan N; Ford K; Langford A; Lawrence N; McDonald W; Rana N; Subramaniam S; Yip S, 2021, '[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', The Lancet, 397, pp. 797 - 804,

Journal articles | 2021

Jiang DM; Fallah-Rad N; Lee R; Ng P; Smith AD; Hansen AR; Joshua AM; Beca J; Sridhar SS, 2021, 'Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer', European Urology, 79, pp. 177 - 179,

Journal articles | 2021

Joshua AM; Baurain J-F; Piperno-Neumann S; Nathan P; Hassel JC; Butler MO; Schlaak M; Sullivan R; Ochsenreither S; Dummer R; Kirkwood JM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Abdullah SE; Deo M; Lockwood S; Rutkowski P, 2021, 'Overall survival benefit from tebentafusp in patients with best response of progressive disease.', JOURNAL OF CLINICAL ONCOLOGY, 39,

Journal articles | 2021

Kelly R; Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua A; Pook D; Baenziger O; Gibbs P; Tran B, 2021, 'Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer', BJU International, 128, pp. 18 - 26,

Journal articles | 2021

Kramer G; Shore N; Joshua A; Li XT; Poehlein C; Schloss C; Bono JD; Yu E, 2021, '419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F', Regular and Young Investigator Award Abstracts, pp. A449 - A449,

Journal articles | 2021

Kramer G; Shore ND; Joshua AM; Li XT; Poehlein CH; Schloss C; de Bono JS; Yu E, 2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F', ANNALS OF ONCOLOGY, 32, pp. S669 - S670,

Journal articles | 2021

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10,

Journal articles | 2021

Lau B; Menzies AM; Joshua AM, 2021, 'Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report', Annals of Oncology, 32, pp. 280 - 282,

Journal articles | 2021

Liang Y; Jeganathan S; Marastoni S; Sharp A; Figueiredo I; Marcellus R; Mawson A; Shalev Z; Pesic A; Sweet J; Guo H; Uehling D; Gurel B; Neeb A; He HH; Montgomery B; Koritzinsky M; Oakes S; De Bono JS; Gleave M; Zoubeidi A; Wouters BG; Joshua AM, 2021, 'Emergence of enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies', Clinical Cancer Research, 27, pp. 2340 - 2351,

Journal articles | 2021

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72,

Journal articles | 2021

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13,

Journal articles | 2021

Naing A; Callahan M; Costello B; Curti B; Hall E; Hansen A; Long G; Joshua A; Shankles B; Ulge U; Ulge U; Weickhardt A, 2021, '509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer', Regular and Young Investigator Award Abstracts, pp. A540 - A540,

Journal articles | 2021

Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S, 2021, 'Overall survival benefit with tebentafusp in metastatic uveal melanoma', New England Journal of Medicine, 385, pp. 1196 - 1206,

Journal articles | 2021

Pham JP; Star P; Wong S; Damian DL; Saw RPM; Whitfeld MJ; Menzies AM; Joshua AM; Smith A, 2021, 'Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor', Skin Health and Disease, 1, pp. e71,

Journal articles | 2021

Piulats J; Ferrario C; Linch M; Stoeckle M; Laguerre B; Arranz J; Todenhoefer T; Fong P; Berry W; Emmenegger U; Mourey L; Mar N; Appleman L; Joshua A; Conter H; Li XT; Schloss C; Poehlein C; Bono JD; Yu E, 2021, '351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)', Regular and Young Investigator Award Abstracts, pp. A378 - A378,

Journal articles | 2021

Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM, 2021, 'Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma', European Journal of Cancer, 144, pp. 182 - 191,

Journal articles | 2021

Sattar S; Haase KR; Bradley C; Papadopoulos E; Kuster S; Santa Mina D; Tippe M; Kaur A; Campbell D; Joshua AM; Rediger C; Souied O; Alibhai S, 2021, 'Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review', Prostate Cancer and Prostatic Diseases, 24, pp. 1007 - 1027,

Journal articles | 2021

Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A, 2021, 'Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease', Asia-Pacific Journal of Clinical Oncology, 17, pp. 36 - 42,

Journal articles | 2021

Shenderov E; Mallesara GHG; Wysocki PJ; Xu W; Ramlau R; Weickhardt AJ; Zolnierek J; Spira A; Joshua AM; Powderly J; Antonarakis ES; Jang S; Aragon-Ching J; Shen J; Paller C; Vogelzang NJ; Leu K; Cortés J; Bohac C; Lugowska I, 2021, '620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion', Annals of Oncology, 32, pp. S657 - S659,

Journal articles | 2021

Shore N; Bono JD; Kramer G; Joshua A; Li XT; Poehlein C; Schloss C; Yu E, 2021, '425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H', Regular and Young Investigator Award Abstracts, pp. A455 - A455,

Journal articles | 2021

Shore ND; Kramer G; Joshua AM; Li XT; Poehlein CH; Schloss C; de Bono JS; Yu E, 2021, 'KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE)', ANNALS OF ONCOLOGY, 32, pp. S669 - S669,

Journal articles | 2021

Smith MR; Sandhu SK; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stahl O; Olmos D; Danila D; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Bevans KB; Lopez-Gitlitz A; Francis P; Fizazi K, 2021, 'Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)', ANNALS OF ONCOLOGY, 32, pp. S632 - S633,

Journal articles | 2021

Subudhi SK; Siddiqui BA; Maly JJ; Nandagopal L; Lam ET; Whang YE; Minocha M; Gupta V; Penny X; Cooner F; Jhones C; Paluch A; Salvati M; Janat-Amsbury M; Eggert T; Kouros-Mehr H; Joshua AM; Aggarwal RR; De Bono JS, 2021, 'Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 39, pp. TPS5088 - TPS5088,

Journal articles | 2021

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID, 2021, 'Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', European Urology, 80, pp. 275 - 279,

Journal articles | 2021

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID, 2021, 'Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', JOURNAL OF UROLOGY, 206, pp. 1519 - 1520,

Journal articles | 2021

Wu SZ; Roden DL; Al-Eryani G; Bartonicek N; Harvey K; Cazet AS; Chan CL; Junankar S; Hui MN; Millar EA; Beretov J; Horvath L; Joshua AM; Stricker P; Wilmott JS; Quek C; Long GV; Scolyer RA; Yeung BZ; Segara D; Mak C; Warrier S; Powell JE; O’Toole S; Lim E; Swarbrick A, 2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13,

Journal articles | 2021

Zhao R; Cosman R; Aggarwal N; O'Grady A; Hsu E; Ardolino L; Xia H; Chi Y; Qui S; Murad Y; Lee E; Jia W; Joshua AM, 2021, 'Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus-VG161.', JOURNAL OF CLINICAL ONCOLOGY, 39,

Journal articles | 2021

de Bono JS; Shore ND; Kramer G; Joshua AM; Li XT; Poehlein CH; Schloss C; Yu EY, 2021, 'Phase Ib/II trial of pembrolizumab (pembro) plus vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H', ANNALS OF ONCOLOGY, 32, pp. S670 - S671,

Journal articles | 2020

Ala-Leppilampi K; Baker NA; McKillop C; Butler MO; Siu LL; Spreafico A; Abdul Razak AR; Joshua AM; Hogg D; Bedard PL; Leighl N; Oza AM; Parsons JA; Hansen AR, 2020, 'Cancer patients’ experiences with immune checkpoint modulators: A qualitative study', Cancer Medicine, 9, pp. 3015 - 3022,

Journal articles | 2020

Alibhai SMH; Breunis H; Timilshina N; Hansen AR; Joshua AM; Warde PR; Gregg RW; Fleshner NE; Tomlinson G; Hotte SJ; Emmenegger U, 2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 38, pp. 73 - 73,

Journal articles | 2020

Ardolino L; Hansen A; Ackland S; Joshua A, 2020, 'Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies', Hormones and Cancer, 11, pp. 155 - 169,

Journal articles | 2020

Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM, 2020, 'Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial', European Urology, 78, pp. 347 - 357,

Journal articles | 2020

Conway MR; Cherepanoff S; Joshua AM, 2020, 'The end of pathology as we know it? (vol 47, pg 163, 2019)', CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 48, pp. 274 - 274,

Journal articles | 2020

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12,

Journal articles | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557,

Journal articles | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120,

Journal articles | 2020

Hamid O; Joshua AM; Hwu W-J; Ribas A; Weber J; Daud AS; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Lin J; Ibrahim N; Carlino M; Robert C, 2020, 'Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma', ANNALS OF ONCOLOGY, 31, pp. S762 - S763,

Journal articles | 2020

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500,

Journal articles | 2020

Hutton-Potts M; Joshua AM, 2020, '2017 ASCO position on the affordability of cancer drugs: Arguments for a major revision', JCO Oncology Practice, 16, pp. 211 - 214,

Journal articles | 2020

Joshua AM; Gurney H; Retz M; Tafreshi A; Fong PCC; Shore ND; Romano E; Augustin M; Piulats JM; Berry WR; Kolinsky MP; Sridhar SS; Conter HJ; Todenhoefer T; Appleman LJ; Wu H; Schloss C; Poehlein CH; de Bono JS; Yu EY, 2020, 'Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study', ANNALS OF ONCOLOGY, 31, pp. S1325 - S1325,

Journal articles | 2020

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073,

Journal articles | 2020

Joshua AM; Tannock IF, 2020, 'Oncology in 2050 – A Retrospective?', Oncologist, 25, pp. e1127 - e1130,

Journal articles | 2020

Man J; Pajic M; Joshua AM, 2020, 'Fats and mets, KRAS-driven lipid dysregulation affects metastatic potential in pancreatic cancer', Cancer Research, 80, pp. 4886 - 4887,

Journal articles | 2020

Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B, 2020, 'Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment', Epigenomics, 12, pp. 1317 - 1332,

Journal articles | 2020

Rodriguez JMP; Patel S; Espinosa E; Pelster MS; Merino LDLC; Khoja LT; Joshua AM; Tebe C; Berrocal A, 2020, '1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials', Annals of Oncology, 31, pp. S764 - S764,

Journal articles | 2020

Romano E; Sridhar SS; Kolinsky MP; Gravis G; Mourey L; Piulats JM; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; de Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Qiu P; Schloss C; Yu EY, 2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update', ANNALS OF ONCOLOGY, 31, pp. S512 - S513,

Journal articles | 2020

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, 10,

Journal articles | 2020

Schmidt AL; Anton A; Wong SS; Azad A; Kwan EM; Spain LA; Torres J; Muthusamy A; Parente P; Parnis F; Goh JC; Joshua AM; Pook DW; Gibbs P; Tran B; Weickhardt AJ, 2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.', Journal of Clinical Oncology, 38, pp. 78 - 78,

Journal articles | 2020

Sridhar SS; Kolinsky MP; Gravis G; Mourey L; Piulats Rodriguez JMM; Romano E; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; De Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Qiu P; Schloss C; Yu EY, 2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.', Journal of Clinical Oncology, 38, pp. 5550 - 5550,

Journal articles | 2020

Wu S; Roden D; Al-Eryani G; Bartonicek N; Harvey K; Cazet A; Chan C-L; Junankar S; Hui M; Millar E; Beretov J; Horvath L; Joshua A; Stricker P; Wilmott J; Quek C; Long G; Scolyer R; Yeung B; Segara D; Mak C; Warrier S; Powell J; O'Toole S; Lim E; Swarbrick A, 2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv,

Journal articles | 2019

Alibhai SMH; Breunis H; Gregg RW; Hansen AR; Warde PR; Timilshina N; Tomlinson G; Joshua AM; Fleshner NE; Emmenegger U, 2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', Journal of Clinical Oncology, 37, pp. 11510 - 11510,

Journal articles | 2019

Ardolino L; Joshua A, 2019, 'Immune checkpoint inhibitors in malignancy', Australian Prescriber, 42, pp. 62 - 67,

Journal articles | 2019

Balzer BWR; Cherepanoff S; Joshua AM; Giblin M; Conway RM; Anazodo AC, 2019, 'Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review', Ocular Oncology and Pathology, 5, pp. 387 - 395,

Journal articles | 2019

Barnet M; Pathmanandavel S; McCarthy L; Goodnow C; Joshua A, 2019, 'The Australian Exceptional Responders Program: A national collaboration', Annals of Oncology, 30, pp. v794 - v795,

Journal articles | 2019

Bavi P; Siva M; Abi-Saab T; Chadwick D; Dhani N; Butany J; Joshua AM; Roehrl MH, 2019, 'Developing a pan-cancer research autopsy programme', Journal of Clinical Pathology, 72, pp. 689 - 695,

Journal articles | 2019

Brown B; Simes J; Boyer M; Hogg P; Joshua A; Young J; Brown C, 2019, 'Psychological Distress in Never, Ex, Current, and Passive Smokers Diagnosed with Lung Cancer - Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S326 - S327,

Journal articles | 2019

Brown B; Simes J; Boyer M; Hogg P; Joshua A; Young J, 2019, 'Embedding Research (and Evidence) in Cancer Healthcare - EnRICH', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S606 - S606,

Journal articles | 2019

Brown B; Simes J; Boyer M; Joshua A; Hogg P; Young J, 2019, 'Patterns of Care in a Prospective Clinical Cohort of Patients with Lung Cancer - Preliminary Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S880 - S880,

Journal articles | 2019

Conway MR; Cherepanoff S; Josua AM, 2019, 'Managing ocular surface neoplasia without biopsy: The end of pathology as we know it?', Clinical and Experimental Ophthalmology, 47, pp. 163 - 164,

Journal articles | 2019

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5,

Journal articles | 2019

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 257 - 261,

Journal articles | 2019

Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Neil Reaume M; Sandhu SK; Tan A; Hsiang Tan T; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ, 2019, 'Enzalutamide with standard first-line therapy in metastatic prostate cancer', New England Journal of Medicine, 381, pp. 121 - 131,

Journal articles | 2019

Day D; Guo C; Kanjanapan Y; Tran B; Spreafico A; Joshua AM; Wang L; Abdul Razak AR; Leighl NB; Hansen AR; Butler MO; Siu LL; Desai J; Bedard PL, 2019, 'Survival in early phase immuno-oncology trials: Development and validation of a prognostic index', JNCI Cancer Spectrum, 3,

Journal articles | 2019

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22,

Journal articles | 2019

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954,

Journal articles | 2019

Fong PCC; Retz M; Drakaki A; Massard C; Berry WR; Romano E; De Bono JS; Feyerabend S; Appleman LJ; Conter HJ; Sridhar SS; Shore ND; Linch MD; Joshua AM; Gurney H; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37,

Journal articles | 2019

Green BJ; Nguyen V; Atenafu E; Weeber P; Duong BTV; Thiagalingam P; Labib M; Mohamadi RM; Hansen AR; Joshua AM; Kelley SO, 2019, 'Phenotypic profiling of circulating tumor cells in metastatic prostate cancer patients using nanoparticle-mediated ranking', Analytical Chemistry, 91, pp. 9348 - 9355,

Journal articles | 2019

Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A, 2019, 'Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001', Annals of Oncology, 30, pp. 582 - 588,

Journal articles | 2019

Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM, 2019, 'Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', Oncologist, 24, pp. 1188 - 1194,

Journal articles | 2019

Hotte SJ; Chi KN; Joshua AM; Tu D; Macfarlane RJ; Gregg RW; Ruether JD; Basappa NS; Finch D; Salim M; Winquist EW; Torri V; North S; Kollmannsberger C; Ellard SL; Eigl BJ; Tinker A; Allan AL; Beja K; Annala M; Powers J; Wyatt AW; Seymour L, 2019, 'A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205', Clinical Genitourinary Cancer, 17, pp. 201 - 208.e1,

Journal articles | 2019

Joshua AM; Tannock IF, 2019, 'Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome', Cancer Cell, 36, pp. 464 - 465,

Journal articles | 2019

Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell M; Chow K; Sherwin B; Stayner LA; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2019, 'Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials', European Journal of Cancer, 107, pp. 1 - 7,

Journal articles | 2019

Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL, 2019, 'Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities', Cancer, 125, pp. 1341 - 1349,

Journal articles | 2019

Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM, 2019, 'Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study', Annals of Oncology, 30, pp. 1370 - 1380,

Journal articles | 2019

Luke JJ; Tabernero J; Joshua A; Desai J; Varga AI; Moreno V; Gomez-Roca CA; Markman B; De Braud FG; Patel SP; Carlino MS; Siu LL; Curigliano G; Liu Z; Ishii Y; Wind-Rotolo M; Basciano PA; Azrilevich A; Gelmon KA, 2019, 'BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).', Journal of Clinical Oncology, 37, pp. 358 - 358,

Journal articles | 2019

Luke* J; Tabernero J; Gelmon K; Varga A; Moreno V; Desai J; Markman B; Gomez-Roca C; De Braud F; Patel S; Carlino M; Siu L; Curigliano G; Liu Z; Ishii Y; Wind-Rotolo M; Basciano P; Azrilevich A; Joshua A, 2019, 'PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER', Journal of Urology, 201,

Journal articles | 2019

Massard C; Retz M; Hammerer P; Quevedo F; Fong PCC; Berry WR; Gurney H; Piulats JM; Joshua AM; Linch MD; Kolinsky MP; Romano E; Sridhar SS; Conter HJ; Augustin M; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37,

Journal articles | 2019

Moreno V; Luke J; Gelmon K; Joshua AM; Varga AI; Desai J; Markman B; Gomez-Roca CA; De Braud F; Patel SP; Carlino MS; Siu LL; Curigliano G; Liu Z; Ishii Y; Wind-Rotolo M; Basciano P; Azrilevich A; Tabernero J, 2019, 'Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup', European Urology Supplements, 18, pp. e1509 - e1510,

Journal articles | 2019

Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO, 2019, 'Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2', Cancer Immunology, Immunotherapy, 68, pp. 773 - 785,

Journal articles | 2019

O’Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ, 2019, 'A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial', British Journal of Cancer, 120, pp. 1113 - 1119,

Journal articles | 2019

Sabesan S; Zalcberg J; Underhill C; Zielinski R; Burbury K; Ansari Z; Rainey N; Collins I; Osbourne R; Sanmugarajah J; Joshua A; Honeyball F; Poxton M; Gebbie C; Marsh SJ; Lusa R; Johnson T; Garbutt A; Bransdon M; Richmond S; Waye R; Cross H; Kent R; Darch J; Brown A, 2019, 'Implementation of the Australasian Teletrial Model: Lessons from practice', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, pp. 3 - 14,

Journal articles | 2019

Sattar S; Alibhai SMH; Brennenstuhl S; Kulik M; MacDonald ME; McWatters K; Lee K; Jang R; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Puts MTE, 2019, 'Health status, emergency department visits, and oncologists’ feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial', Journal of Geriatric Oncology, 10, pp. 169 - 174,

Journal articles | 2019

Sattar S; Haase K; Bradley C; Papadopoulos E; Kuster S; Mina DS; Joshua A; Souied O; Rediger C; Alibhai S, 2019, 'PERCEPTION OF STRUCTURED EXERCISE PROGRAMS AND FACTORS ASSOCIATED WITH PARTICIPATION AND ADHERENCE AMONG MEN WITH PROSTATE CANCER: A SCOPING REVIEW', Journal of Geriatric Oncology, 10, pp. S98 - S98,

Journal articles | 2019

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia-Pacific Journal of Clinical Oncology, 15, pp. 3 - 10,

Journal articles | 2019

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397,

Journal articles | 2019

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396,

Journal articles | 2019

Yu EY; Massard C; Retz M; Tafreshi A; Carles Galceran J; Hammerer P; Fong PCC; Shore ND; Joshua A; Linch MD; Gurney H; Romano E; Augustin M; Piulats JM; Wu H; Schloss C; Poehlein CH; De Bono JS, 2019, 'Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 37, pp. 145 - 145,

Journal articles | 2019

Yu EY; Massard C; Retz M; Tafreshi A; Carles J; Hammerer P; Fong PCC; Shore ND; Joshua AM; Linch MD; Gurney H; Romano E; Augustin M; Piulats JM; Wu H; Schloss C; Poehlein CH; De Bono JS, 2019, 'Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37,

Journal articles | 2018

Aung KL; Bedard PL; Yu C; Boerner SL; Zuzarte PC; Ghai S; Berman HK; Serra S; Giesler A; Ahmed L; Joshua AM; Moore MJ; Oza AM; Amir E; McPherson JD; Zhang T; Sukhai MA; Stockley TL; Kamel-Reid S; Siu LL; Hansen AR, 2018, 'Minimally invasive real-time detection of actionable mutations in patients with metastatic solid tumors using fine-needle and liquid biopsies', JCO Precision Oncology, 2, pp. 1 - 20,

Journal articles | 2018

Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N, 2018, 'Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer', Urologic Oncology: Seminars and Original Investigations, 36, pp. 240.e13 - 240.e20,

Journal articles | 2018

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737,

Journal articles | 2018

Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ, 2018, 'Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer', Clinical Genitourinary Cancer, 16, pp. 130 - 134,

Journal articles | 2018

Gordevicius J; Krisci unas A; Groot DE; Yip SM; Susic M; Kwan A; Kustra R; Joshua AM; Chi KN; Petronis A; Oh G, 2018, 'Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients', Clinical Cancer Research, 24, pp. 3317 - 3324,

Journal articles | 2018

Hamid O; Robert C; Daud A; Hodi FS; Hwu W-J; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca RS; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Jensen E; Ibrahim N; Ahsan S; Ribas A, 2018, '5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.', Journal of Clinical Oncology, 36, pp. 9516 - 9516,

Journal articles | 2018

Joseph RW; Elassaiss-Schaap J; Kefford R; Hwu WJ; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid O; Robert C; Daud A; Dronca R; Hersey P; Weber JS; Patnaik A; De Alwis DP; Perrone A; Zhang J; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC, 2018, 'Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab', Clinical Cancer Research, 24, pp. 4960 - 4967,

Journal articles | 2018

Joseph RW; Elassaiss-Schaap J; Kefford R; Hwu WJ; Wolchok JD; Joshua AM; Ribas A; Stephen Hodi F; Hamid O; Robert C; Daud A; Dronca R; Hersey P; Weber JS; Patnaik A; de Alwis DP; Perrone A; Zhang J; Peter Kang S; Ebbinghaus S; Anderson KM; Gangadhar TC, 2018, 'Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)', Clinical Cancer Research, 24, pp. 6098,

Journal articles | 2018

Lorente D; De Velasco Oria GA; Carles J; Gillessen S; Fizazi K; Joshua A; Eisenberger M; Sartor O; de Bono JS, 2018, 'Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. viii279 - viii280,

Journal articles | 2018

Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM, 2018, 'Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience', Melanoma Research, 28, pp. 571 - 577,

Journal articles | 2018

Niraula S; Templeton AJ; Vera-Badillo F; Dodd A; Nugent Z; Joshua AM; Tannock IF, 2018, 'Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer', Future Science OA, 4,

Journal articles | 2018

Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H, 2018, 'Oncogenic signaling in uveal melanoma', Pigment Cell and Melanoma Research, 31, pp. 661 - 672,

Journal articles | 2018

Puts MTE; Sattar S; Kulik M; MacDonald ME; McWatters K; Lee K; Brennenstuhl S; Jang R; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Alibhai SMH, 2018, 'A randomized phase II trial of geriatric assessment and management for older cancer patients', Supportive Care in Cancer, 26, pp. 109 - 117,

Journal articles | 2018

Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS, 2018, 'Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma', Journal of Clinical Oncology, 36, pp. 1668 - 1674,

Journal articles | 2018

Tabernero J; Luke JJ; Joshua AM; Varga AI; Moreno V; Desai J; Markman B; Gomez-Roca CA; De Braud FG; Patel SP; Carlino MS; Siu LL; Curigliano G; Liu Z; Ishii Y; Phillips P; Wind-Rotolo M; Basciano PA; Azrilevich A; Gelmon KA, 2018, 'BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).', Journal of Clinical Oncology, 36, pp. 4512 - 4512,

Journal articles | 2018

Tannock IF; Joshua AM, 2018, 'Purchasing silence', Annals of Oncology, 29, pp. 1339 - 1340,

Journal articles | 2018

Tio M; Rai R; Ezeoke OM; McQuade JL; Zimmer L; Khoo C; Park JJ; Spain L; Turajlic S; Ardolino L; Yip D; Goldinger SM; Cohen JV; Millward M; Atkinson V; Kane AY; Ascierto PA; Garbe C; Gutzmer R; Johnson DB; Rizvi HA; Joshua AM; Hellmann MD; Long GV; Menzies AM, 2018, 'Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection', European Journal of Cancer, 104, pp. 137 - 144,

Journal articles | 2018

Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN, 2018, 'A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer', Investigational New Drugs, 36, pp. 278 - 287,

Journal articles | 2017

Atkinson TM; Hay JL; Shoushtari A; Li Y; Paucar DJ; Smith SC; Kudchadkar RR; Doyle A; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Marr B; Abramson DH; Dickson MA; Schwartz GK; Carvajal RD, 2017, 'Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma', Journal of Cancer Research and Clinical Oncology, 143, pp. 439 - 445,

Journal articles | 2017

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, pp. 34,

Journal articles | 2017

Emmett L; Van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P, 2017, 'Treatment outcomes from ⁶⁸Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET', Journal of Nuclear Medicine, 58, pp. 1972 - 1976,

Journal articles | 2017

Fallah-Rad N; Lee R; Ng P; Smith AD; Hansen AR; Joshua AM; Sridhar SS, 2017, 'Strategies to minimize wastage of expensive drugs in expensive times: Cabazitaxel, a single center experience.', Journal of Clinical Oncology, 35, pp. e18297 - e18297,

Journal articles | 2017

Francini E; Yip S; Ahmed NS; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff P; Taplin ME; Alimohamed N; Joshua AM; Heng DYC; Sweeney CJ, 2017, 'Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry', ANNALS OF ONCOLOGY, 28,

Journal articles | 2017

Gwadry-Sridhar F; Nikan S; Hamou A; Seung SJ; Petrella T; Joshua AM; Ernst S; Mittmann N, 2017, 'Resource utilization and costs of managing patients with advanced melanoma: A canadian population-based study', Current Oncology, 24, pp. 168 - 175,

Journal articles | 2017

Kanjanapan Y; Day D; Butler M; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell MA; Chow K; Paolo M; Sherwin B; Stayner L-A; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2017, 'Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination', Annals of Oncology, 28, pp. v132 - v132,

Journal articles | 2017

Khoja L; Atenafu E; Joshua AM; Ocular Melanoma Group IRCI, 2017, 'Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative', Annals of Oncology, 28, pp. v439 - v439,

Journal articles | 2017

Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; Van Der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH, 2017, 'LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression', Cancer Research, 77, pp. 5479 - 5490,

Journal articles | 2017

Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME, 2017, 'Neoadjuvant enzalutamide prior to prostatectomy', Clinical Cancer Research, 23, pp. 2169 - 2176,

Journal articles | 2017

Pitcher B; Khoja L; Hamilton RJ; Abdallah K; Pintilie M; Joshua AM, 2017, 'Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)', PLoS ONE, 12,

Journal articles | 2017

Poudineh M; Aldridge PM; Ahmed S; Green BJ; Kermanshah L; Nguyen V; Tu C; Mohamadi RM; Nam RK; Hansen A; Sridhar SS; Finelli A; Fleshner NE; Joshua AM; Sargent EH; Kelley SO, 2017, 'Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking', Nature Nanotechnology, 12, pp. 274 - 281,

Journal articles | 2017

Puts MTE; Sattar S; McWatters K; Lee K; Kulik M; MacDonald ME; Jang R; Amir E; Krzyzanowska MK; Leighl N; Fitch M; Joshua AM; Warde P; Tourangeau AE; Alibhai SMH, 2017, 'Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study', Supportive Care in Cancer, 25, pp. 879 - 886,

Journal articles | 2017

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2017, 'Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity', Cancer Chemotherapy and Pharmacology, 79, pp. 959 - 969,

Journal articles | 2017

Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN, 2017, 'AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate', Journal of Urology, 197, pp. 135 - 142,

Journal articles | 2016

Azad A; Todenhöfer T; Stewart C; Gao J; Eigl BJ; Black PC; Joshua AM; Chi KN, 2016, 'Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).', Journal of Clinical Oncology, 34, pp. e23075 - e23075,

Journal articles | 2016

Chi KN; Kheoh T; Ryan CJ; Molina A; Bellmunt J; Vogelzang NJ; Rathkopf DE; Fizazi K; Kantoff PW; Li J; Azad AA; Eigl BJ; Heng DYC; Joshua AM; de Bono JS; Scher HI, 2016, 'A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel', Annals of Oncology, 27, pp. 454 - 460,

Journal articles | 2016

Chung C; Khoja L; Kurtz G; Bernstein M; Joshua A; Hogg D; Zadeh G; Laperriere N; Menard C; Millar BA; Kongkham P; Butler M, 2016, 'Local Tumor Flare Following Radiosurgery and Ipilimumab (Ipi) for Melanoma Brain Metastases: Increased Immune Response?', RADIOTHERAPY AND ONCOLOGY, 118, pp. S26 - S26,

Journal articles | 2016

Corfield J; Crozier J; Joshua A; Bolton D; Lawrentschuck N, 2016, 'Understanding the role of new systemic agents in the treatment of prostate cancer', BJU International, 118, pp. 8 - 13,

Journal articles | 2016

Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O, 2016, 'Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma', Journal of Clinical Oncology, 34, pp. 4102 - 4109,

Journal articles | 2016

Ernst DS; Petrella T; Joshua AM; Hamou A; Thabane M; Vantyghem S; Gwadry-Sridhar F, 2016, 'Burden of illness for metastatic melanoma in Canada, 2011–2013', Current Oncology, 23, pp. e563 - e570,

Journal articles | 2016

Hageman MGJS; Bossen JK; Neuhaus V; Mudgal CS; Ring D; Joshua AM; Adams J; Arbelaez GF; Aspard T; Balfour GW; Bamberger BH; Romero JCB; Baskies M; Batson AW; Baxamusa T; De Bedout R; Beldner S; Benhaim P; Benson L; Boretto JG; Boyer M; Dee GB; Calfee RP; Zambrano CGC; Cassidy C; Catalano L; Chivers K; Costanzo RM; Dantuluri P; DeSilva G; Dodds S; Evans JP; Escobar LFN; Fernandes CH; Fischer TJ; Fischer J; Fricker RM; Frykman GK; Garcia AE; Gaston GR; Giovanni Di FJ; Goldfarb CA; Grafe MW; Grunwald HW; Hammert WC; Hauck R; Hernandez RG; Hofmeister E; Hutchison RL; Ilyas A; Isaacs J; Jacoby SM; Jebson P; Jones CM; Jones M; Kakar S; Kalainov DM; Thomas KD; Kaplan S; Katolik L; Kennedy SA; Kessler MW; Kimball HL; Kraan GA; Martineau PA; McAuliffe J; McCabe SJ; McKee DM; Merrell G; Metzger C; Nancollas M; Nelson DL; Nyszkiewicz R; Ortiz JA; Owens PW; Palmer JM; Paz L; Pess GM; Polatsch D; Frank Raia J; Richard MJ; Rizzo M; Rozental ; Ruchelsman D; Semenkin OM; Aguilar JFS; Siff T; Sodha S; Spath C; Spruijt S; Stackhouse TG; Swigart C; Szabo RM; Taras J; Tavakolian JD; Terrono AL; Varecka TF; Wahegaonkar AL; Walsh CJ; Walter FL, 2016, 'Assessment of decisional conflict about the treatment of carpal tunnel syndrome, comparing patients and physicians', Archives of Bone and Joint Surgery, 4, pp. 150 - 155

Journal articles | 2016

Hodi FS; Hwu WJ; Kefford R; Weber JS; Daud A; Hamid O; Patnaik A; Ribas A; Robert C; Gangadhar TC; Joshua AM; Hersey P; Dronca R; Joseph R; Hille D; Xue D; Li XN; Kang SP; Ebbinghaus S; Perrone A; Wolchok JD, 2016, 'Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab', Journal of Clinical Oncology, 34, pp. 1510 - 1517,

Journal articles | 2016

Khoja L; Atenafu EG; Joshua AM, 2016, 'Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative.', Journal of Clinical Oncology, 34, pp. 9567 - 9567,

Journal articles | 2016

Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM, 2016, 'The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma', Cancer Medicine, 5, pp. 2792 - 2799,

Journal articles | 2016

Khoja L; Atenafu EG; Ye Q; Gedye C; Chappell M; Hogg D; Butler MO; Joshua AM, 2016, 'Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma', Oncology Letters, 11, pp. 1581 - 1585,

Journal articles | 2016

Khoja L; Kibiro M; Metser U; Gedye C; Hogg D; Butler MO; Atenafu EG; Joshua AM, 2016, 'Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients', British Journal of Cancer, 115, pp. 1186 - 1192,

Journal articles | 2016

Khoja L; Maurice C; Chappell M; Macmillan L; Al-Habeeb AS; Al-Faraidy N; Butler MO; Rogalla P; Mason W; Joshua AM; Hogg D, 2016, 'Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma', Cancer Immunology Research, 4, pp. 175 - 178,

Journal articles | 2016

Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM, 2016, 'Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: A post hoc analysis of an extension cohort of a phase II trial', Journal of Translational Medicine, 14, pp. 12,

Journal articles | 2016

Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SMH, 2016, 'A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone', Journal of Geriatric Oncology, 7, pp. 81 - 89,

Journal articles | 2016

Nicholas M; Khoja L; Hogg D; Quirt I; Butler MO; Joshua AM, 2016, 'Prognosticators of first line treatment for metastatic uveal melanoma (MUM).', Journal of Clinical Oncology, 34, pp. 9570 - 9570,

Journal articles | 2016

Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF, 2016, 'Study of testosterone-guided androgen deprivation therapy in management of prostate cancer', Prostate, 76, pp. 235 - 242,

Journal articles | 2016

Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C, 2016, 'Association of pembrolizumab with tumor response and survival among patients with advanced melanoma', JAMA - Journal of the American Medical Association, 315, pp. 1600 - 1609,

Journal articles | 2016

Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Li XN; Diede SJ; Ebbinghaus S; Hodi S, 2016, 'Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète', Annales de Dermatologie et de Vénéréologie, 143, pp. S209 - S210,

Journal articles | 2016

Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph RW; Dronca RS; Patnaik A; Zarour HM; Kefford R; Hersey P; Li X; Diede SJ; Ebbinghaus S; Hodi FS, 2016, 'Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.', Journal of Clinical Oncology, 34, pp. 9503 - 9503,

Journal articles | 2016

Singnurkar A; Wang J; Joshua AM; Langer DL; Metser U, 2016, '¹⁸F-FDG-PET/CT in the staging and management of melanoma a prospective multicenter Ontario PET registry study', Clinical Nuclear Medicine, 41, pp. 189 - 193,

Journal articles | 2016

Smith AD; Truong M; Bristow R; Yip P; Milosevic MF; Joshua AM, 2016, 'The utility of serum ca9 for prognostication in prostate cancer', Anticancer Research, 36, pp. 4489 - 4492,

Journal articles | 2016

Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak ARA; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL, 2016, 'Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT/COMPACT trial', Genome Medicine, 8,

Journal articles | 2016

Todenhöfer T; Azad A; Gao J; Stewart C; Eigl B; Stenzl A; Black P; Teich M; Joshua A; Chi K, 2016, '774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)', European Urology Supplements, 15, pp. e774 - e774,

Journal articles | 2016

Todenhöfer T; Azad A; Gao J; Stewart C; Eigl B; Stenzl A; Teich M; Black P; Joshua A; Chi K, 2016, 'PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI)', Journal of Urology, 195,

Journal articles | 2015

Alibhai SMH; Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM, 2015, 'Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?', Journal of Clinical Oncology, 33, pp. e20528 - e20528,

Journal articles | 2015

Attard G; De Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; Van Den Eertwegh AJM; Li W; Molina A; Griffin TW; Kheoh T; Ricci DS; Zelinsky K; Rathkopf DE; Scher HI; Ryan CJ, 2015, 'Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate', Clinical Cancer Research, 21, pp. 1621 - 1627,

Journal articles | 2015

Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DYC; Joshua AM; Chi KN, 2015, 'Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status', European Urology, 67, pp. 441 - 447,

Journal articles | 2015

Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Carles J; Mainwaring PN; Evans CP; Parli T; Mansbach HH; Bhattacharya S; Van Os S; Phung D; TOMBAL BF, 2015, 'Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.', Journal of Clinical Oncology, 33, pp. 5036 - 5036,

Journal articles | 2015

Benidir T; Finelli A; Hamilton R; Hersey K; Joshua A; Kulkarni G; Zlotta A; Fleshner N, 2015, 'MP73-02 PATIENT UNDERSTANDING REGARDING END-OF-LIFE PROSTATE CANCER AND PERSPECTIVES REGARDING COST/BENEFIT OF CURRENT TREATMENT PARADIGMS', Journal of Urology, 193,

Journal articles | 2015

Chi K; Hotte SJ; Joshua AM; North S; Wyatt AW; Collins LL; Saad F, 2015, 'Treatment of mCRPC in the AR-axis-targeted therapy-resistant state', Annals of Oncology, 26, pp. 2044 - 2056,

Journal articles | 2015

Daud A; Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph RW; Dronca RS; Patnaik A; Zarour HM; Kefford R; Lindia JA; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', Journal of Clinical Oncology, 33, pp. 9005 - 9005,

Journal articles | 2015

Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T, 2015, 'A phase 2 study of tremelimumab in patients with advanced uveal melanoma', Melanoma Research, 25, pp. 342 - 347,

Journal articles | 2015

Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D, 2015, 'Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America', Prostate, 75, pp. 836 - 844,

Journal articles | 2015

Khoja L; Butler MO; Chappell MA; Hogg D; Joshua AM, 2015, 'Increased treatment-related toxicity subsequent to an anti–PD-1 agent', Current Oncology, 22, pp. e320 - e322,

Journal articles | 2015

Khoja L; Butler MO; Kang SP; Ebbinghaus S; Joshua AM, 2015, 'Pembrolizumab', Journal for ImmunoTherapy of Cancer, 3,

Journal articles | 2015

Khoja L; Kurtz G; Bernstein M; Joshua AM; Hogg D; Zadeh G; Laperriere N; Menard C; Miller B-A; Kongkham PN; Atenafu EG; Butler MO; Chung C, 2015, 'Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?', Journal of Clinical Oncology, 33, pp. e20019 - e20019,

Journal articles | 2015

Kibiro M; Khoja L; Hogg D; Butler MO; Metser U; Atenafu EG; Joshua AM, 2015, 'Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM).', Journal of Clinical Oncology, 33, pp. 9073 - 9073,

Journal articles | 2015

Leibowitz-Amit R; Khoja L; Tannock IF; Joshua AM, 2015, 'Choosing a better end point for trials of bone-protective agents', Annals of Oncology, 26, pp. 1032 - 1033,

Journal articles | 2015

Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM, 2015, 'Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer', Journal of Geriatric Oncology, 6, pp. 23 - 28,

Journal articles | 2015

Manusow JS; Khoja L; Pesin N; Joshua AM; Mandelcorn ED, 2015, 'Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma', Journal for ImmunoTherapy of Cancer, 2,

Journal articles | 2015

McWhirter E; Hamid O; Chmielowski B; Carvajal RD; Jaffray DA; Driscoll B; Shek T; Yeung I; Keller H; McKee TD; Pearce TE; Kroll S; Joshua AM, 2015, 'A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.', Journal of Clinical Oncology, 33, pp. TPS9089 - TPS9089,

Journal articles | 2015

Power NE; Willie C; Mazzola CR; Tailly T; Sonke E; Pardhan S; Tram A; Brugarolas J; Sener A; Chambers AF; Pautler SE; Leong H; Punjani N; Power NE; Vanhie J; Winquist E; Siemens DR; William M; Wei X; Peng P; Booth CM; Gakis G; Morgan T; Daneshmand S; Keegan K; Clayman R; Mischinger J; Zaid H; Hrbacek J; Ali-El-Dein B; Galland S; Olugbade K; Rink M; Fritsche H-M; Burger M; Chang S; Babjuk M; Thalmann G; Stenzl A; Efstathiou J; Nayak JG; Patel P; Saarela O; Liu Z; Kapoor A; Tanguay S; Finelli A; Rendon RA; Moore R; Breau RH; Kawakami J; Black PC; Drachenberg DE; Matta R; Al Matar A; Bhindi B; Zlotta A; Fleshner N; Jewett M; Hamilton RJ; Finelli A; Kulkarni GS; Lee JK; Sjoberg DD; Thong A; Mulhall JP; Sandhu J; Vickers AJ; Ehdaie B; Elkoushy M; Elshal A; Elhiali M; Azizi M; Hai MA; Gonzalez RR; Eure GR; Kriteman LS; Hueber P-A; Alenizi AM; Bienz M; El Hosni K; Meskawi M; Zorn KC; Radomski S; De Ridder D; Sussman D; Sand P; Sievert K-D; Chapple CR; Nicandro JP; Zhou J; Nitti V; Maciejewski C; Haines T; Rourke KF; Zappavigna CJ; Herschorn S; Braga LH; D’Cruz J; Jegatheeswaran K; DeMaria JE; Lorenzo A; Salle JLP; Kim S; Dave S; Liu K; Mamut A; Shariff S; Braga LH; D’Cruz J; Farrokhyar F; Rickard M; DeMaria JE; Lorenzo A; Hueber P-A; Abdo A; Franc-Guimond J; Barrieras JD; Houle A-M; Koyle M; Lorenzo A; Farhat WA; Beamish T; Gainey S; Rowed S; Odeh R; Alyami F; Koyle M; Farhat WA; Rocha J; Aprikian A; Vanhuyse M; Cury F; Kassouf W; Dragomir A; Hamilton RJ; Ding K; Crook J; O’Callaghan CJ; Higano CS; Dearnaley D; Horwitz E; Goldenberg SL; Gospodarowicz M; Klotz L; Violette P; Agoritsas T; Riikonen J; Santti H; Alexander P; Agarwal A; Bhatnagar N; Dahm P; Montori V; Guyatt GH; Kari TAO; Richard P; Alibhai SM; Urbach D; Fleshner N; Tamilshina N; Klotz L; Finelli A; Savdie R; Aning J; So A; Black PC; Gleave M; Goldenberg SL; Da Silva VC; Cagiannos I; Mallick R; Witiuk K; Cnossen S; Fergusson D; Morash C; Breau RH; Siemens DR; Heidenreich A; Klotz L; Villers A; van Os S; Phung D; Wang F; Bhattacharya S; Chowdhury S; Shore N; Noureldin Y; Elkoushy M; Andonian S; Knudsen BE; Miller NL; Yong C; Wang A; Charchenko C; Humphreys MR; Krambeck AE; Chew BH; Brotherhood HL; Sur RL; Penniston KL; Antonelli JA; Averch TD; Chew BH; Pais VM; Viprakasit DP; Sur RL; Bird VG; Nakada SY; Roberts G; Leslie RJ; Robb S; Beiko DT; Streeper NM; Lim AH; Best SL; Penniston KL; Nakada SY; Olvera-Posada D; Alenezi H; Tailly T; Violette P; Pautler SE; Denstedt J; Razvi H; Cristea OM; Stokl A; Montroy J; Cnossen S; Mallick R; Cagiannos I; Morash C; Breau RH; Billia M; Pahernik S; Relle J; Burtnyk M; Röthke M; Hafron J; Schlemmer H-P; Chin LKJ; Ghai S; Finelli A; McCluskey S; Hlasny E; Corr K; Nesbitt M; Van der Kwast T; Kucharczyk W; Zlotta A; Trachtenberg J; Cerantola Y; Haberer E; Torres J; Alameldin M; Aronson S; Levental M; Bladou F; Anidjar M; Dragomir A; Cerantola Y; Tanguay S; Bladou F; Aprikian A; Kassouf W; Alenizi AM; Valdivieso R; Rajih E; Meskawi M; Taorta C; Bienz M; Hueber P-A; Lavigueur-Blouin H; Trudeau V; El-Hakim A; Zorn KC; Gevariya NR; Bergeron A; Besançon M; Picard V; Leger C; Fradet Y; Al Esawi A; Fradet V; O’Malley PG; Al Hussein Al Awamlh B; Sarkisian AM; Jin S; Nguyen DP; Lee R; Scherr DS; Barbieri CE; Herman M; Toarta C; Bienz M; Trudeau V; Alesawi A; Valdivieso R; Hueber P-A; Alenizi AM; Trinh Q-D; El-Hakim A; Zorn KC; Wallis CJ; Mahar A; Cheung P; Herschorn S; Klotz L; Al-Matar A; Kulkarni GS; Lee Y; Kodama RT; Narod SA; Nam RK; Dason SR; Allard CB; Shayegan B; Alkasab T; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Jewett M; Fleshner N; Bjazevic J; Kaler K; Rittberg R; Saranchuk JW; Drachenberg DE; Boehm K; Meskawi M; Valdivieso R; Larcher A; Sun M; Graefen M; Saad F; Parent M-É; Karakiewicz PI; Liberman D; Jarosek SL; Virnig BA; Elliott SP; Saad F; Ivanescu C; Phung D; Loriot Y; Mansbach H; Beer TM; Tombal B; Holmstrom S; Timilshina N; Alibhai S; Ouellet V; Delvoye N; Drachenberg DE; Finelli A; Jammal M-P; Lapointe H; Li K; Lynch K; Mes-Masson A-M; Paradis JB; Sitarik P; So A; Sutcliffe S; Saad F; Fitch M; Pang K; Ouellet V; Mes-Masson A-M; Chevalier S; Drachenberg DE; Finelli A; Hamel L; Li K; Palmer M; Sitarik P; Sutcliffe S; So A; Tanguay S; Saad F; Akhter W; Khan MJMJ; Moghul M; Karim OO; Laniado MM; Ray AA; Foell KA; Hartsburg CJ; Zadra J; Iocca AJ; Marzouk K; Whelan TF; Hasan T; McBriarty H; Webster TM; Newell K; Wang Y; Hoogenes J; Wu CH; Shayegan B; Alkasab T; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Jewett M; Fleshner N; Rediger C; Bella A; Flannigan R; Bieniek J; Mullen B; Grober ED; Lo K; Jarvi K; Flannigan R; Bieniek J; Jarvi K; Grober ED; Lo K; Mullen B; Singh HHK; Baverstock R; Weber BA; Carlson K; Liberman D; Broghammer J; Smith TG; Voelzke BB; Erickson BA; McClung C; Alsikafi N; Vanni A; Myers J; Elliott SP; Liberman D; Pagliara T; Myers J; Stoffel JT; Elliott SP; Zappavigna CJ; Herschorn S; Zappavigna CJ; Herschorn S; Feldman R; Denes BS; Shultz T; Millar A; Elterman DS; Jarvi K; Elterman DS; Millar A; Jarvi K; Forbes EC; Rourke KF; Shahrour W; Joshi P; Hunter CB; Batra V; Suranah S; Kulkarni S; Rourke KF; Kinnaird A; Chapman D; Haines T; Rourke KF; Wong N; Allard CB; Davies TO; Hoy NY; Rourke KF; Tran H; Flannigan R; Rapoport D; Telb M; Shabana W; Dawod T; Shahin A; Eladl M; Shabana W; Dawod T; Telb M; Shahin A; Eladl M; Alenizi AM; Bienz M; Rajih E; Al-Hathal N; Zorn KC; El-Hakim A; Alenizi AM; Bienz M; Rajih E; Alesawi A; Al-Hathal N; Benayoun S; Lebeau T; Zorn KC; El-Hakim A; Chew BH; Flannigan R; Kurtz MP; Arsovska O; Paterson RF; Eisner B; Lange D; Noureldin Y; Elkoushy M; Andonian S; Noureldin Y; Elkoushy M; Andonian S; Soueidan M; Susan JB; Noureldin Y; Ross EA; Andonian S; Kroczak TJ; Kaler K; Patel P; Al Essawi T; Brodie A; Moghul M; Akhter W; Kalsi J; Tailly T; Larish Y; Nadeau BR; Olvera-Posada D; Alenezi H; Violette P; Glickman L; Amann J; Denstedt J; Razvi H; Alzahrani TM; Ghiculete D; Pace KT; Lee JY; Honey RJD; Alzahrani TM; Ghiculete D; Garbens A; Pace KT; Honey RJD; Alzahrani TM; Ghiculete D; Pace KT; Honey RJD; Kokorovic A; Fuoco MB; Wilson JW; Beiko DT; Althunayan AM; Barrett KP; Honey RJD; Althunayan AM; Ghiculete D; Lee JY; Ordon MH; Honey RJD; Pace KT; Barrett KP; Ghiculete D; Ordon MH; Lee JY; Pace KT; Honey RJD; Barrett KP; Honey RJD; Barrett KP; Ghiculete D; Ordon MH; Lee JY; Pace KT; Honey RJD; Akerman JP; Tu HYV; Hoogenes J; Lambe SA; Matsumoto ED; Chaparala H; Mohamed O; Monga M; Sivalingam S; Kartha GK; Chaparalla H; Calle JC; Monga M; Sivalingam S; Tu HYV; Matsumoto ED; Chew BH; Harriman DI; Lange D; Arsovska O; McDougall E; Paterson RF; Chew BH; McLaughlin PD; Paterson RF; McDougall E; Nugent J; Rowley VA; Buckley J; Zwirewich C; Dawod T; Shabana W; Telb M; Shahin A; Eladl M; Shabana W; Dawod T; Telb M; Shahin A; Eladl M; Patel P; Kaler K; Pruthi D; Kirkpatrick I; Radulovic D; McGregor TB; Alomar l. MA; Tawhary M; Alomar A; Mohammad A; Alenezi H; Nott L; Olvera-Posada D; Tailly T; Pautler SE; Razvi H; Denstedt J; Mittal AA; Tandon SS; Singla SS; Tandon CC; Pruthi D; Chhibba R; Drachenberg DE; McGregor TB; Pruthi D; Liu V; Chhibba R; Gibson I; McGregor TB; Bhatt J; Avery J; Basiuk J; Laupacis A; Cowan K; Weller A; Al Asaaed S; Canil C; Jewett M; Jones J; Allard CB; Kuppermann D; Psutka S; Wu P; Dhyani M; McGovern FJ; McDougal WS; Gervais D; Mueller P; Blute ML; Feldman AS; Lavallee LT; Fitzpatrick RM; Witiuk K; Wood LA; Basiuk J; Vanhuyse M; Tanguay S; Pautler SE; Finelli A; Jewett M; Cagiannos I; Morash C; Breau RH; Richard P; Jewett M; Bhatt J; Evans A; Tamilshina N; Finelli A; Rowe NE; McLarty R; Costello P; McDonald W; Luke PP; Rowe NE; McLarty R; Costello P; McDonald W; Luke PP; Rudzinski JK; Basappa N; Heng DYC; North S; Nayak JG; Patel P; Bjazevic J; Liu Z; Saarela O; Kapoor A; Finelli A; Rendon RA; Tanguay S; Black PC; Breau RH; Kawakami J; Moore R; Drachenberg DE; Dragomir A; Cerantola Y; Kapoor A; Finelli A; Jewett M; Rendon RA; Black PC; Moore R; Kawakami J; Drachenberg DE; Lacombe L; Breau RH; Klotz L; Pautler SE; Lattouf J-B; Aprikian A; Tanguay S; Campbell JD; Luke PP; Trudeau V; Larcher A; Sun M; Boehm K; Meskawi M; Tian Z; Dell’Oglio P; Karakiewicz PI; Trudeau V; Larcher A; Sun M; Boehm K; Dell’Oglio P; Meskawi M; Karakiewicz PI; Trudeau V; Larcher A; Sun M; Meskawi M; Boehm K; Valdivieso R; Tian Z; Karakiewicz PI; Trudeau V; Larcher A; Meskawi M; Valdivieso R; Boehm K; Tian Z; Sun M; Karakiewicz PI; Trudeau V; Larcher A; Fossati N; Tian Z; Popa I; Boehm K; Meskawi M; Valdivieso R; Sun M; Karakiewicz PI; Meskawi M; Valdivieso R; Larcher A; Sun M; Karakiewicz PI; Meskawi M; Valdivieso R; Trudeau V; Sun M; Karakiewicz PI; Aubé M; Bui B; Sabbagh R; Rowe NE; McLarty R; Costello P; McDonald W; Luke PP; Billia M; Mazzola CR; Siddiqui K; Joseph CLK; Ouellet S; Sabbagh R; Carmel M; Jeldres C; Bastiampillai RJ; Lavallee LT; Witiuk K; Mallick R; Fergusson D; Schram D; Morash C; Cagiannos I; Breau RH; Cerantola Y; Ploussard G; Kassouf W; Anidjar M; Bladou F; Pruthi D; Drachenberg DE; Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Faiena I; Modi P; Chung BI; Singer EA; Chang SL; Allard CB; Coret A; Dason SR; Tajzler C; Shayegan B; Matsumoto ED; Kapoor A; Li J; Zhang Q; Pautler SE; Izawa J; Gomez-Lemus J; Leong H; Power NE; Clark RK; Rendon RA; Clark RK; Acker MR; Raha D; Rendon RA; Orabi H; Rousseau A; Bolduc S; Lee JY; Blankstein U; Hoang R; Ordon MH; Pace KT; Lantz AG; Blankstein U; Andrews JM; Honey RJD; Ordon MH; Pace KT; Lee JY; Law J; Rowe NE; Nastis S; Luke PP; McAlpine K; Steele SS; Rourke KF; MacNeily A; Nayak JG; Hartzler A; Izard JP; Dalkin BL; Gore JL; Aboalsamh GA; Lobb I; Saha M; Whiteman M; Luke PP; Sener A; Aboalsamh GA; May M; Archambault J; Sener A; Luke PP; Noureldin Y; Elkoushy M; Andonian S; Farcas MA; Maeve OT; Nasr A; Gerstle JT; Carrillo B; Azzie G; Loeb S; Matta R; Azevedo N; Tong S; Doiron RC; Leveridge MJ; Leveridge MJ; Thangasamy I; Davies B; Finelli A; Stork B; Loeb S; Woo H; Gajewski J; Mason R; Whelan TF; Carlson K; Civitarese A; Yanko D; Desantis D; Crump T; Baverstock R; Patel P; Nayak JG; McGregor TB; Courtemanche K; Chan P; Kassouf W; Abara E; Noushi N; Abara E; Abara E; El-Sherbini M; Abara E; Kanaroglou N; Wehbi E; Rwamasirabo E; Duke L; Sourial M; Ntakiyiruta G; Orabi H; Rousseau A; Morissette A; Bouchard F; Fortin M-C; Bolduc S; Aldousari S; Almarzouq A; Al-Yousef RJ; Abul F; Hussein SA; Thalib L; Natarajan S; Arun N; Kim S; Hoogenes J; Elias R; Kim K; Shayegan B; Piercey KR; Kapoor A; Sonnadara R; Matsumoto ED; Monica VF; Cammisotto P; Campeau L; Monica VF; Cammisotto P; Campeau L; Monica VF; Cammisotto P; Campeau L; Siddiqui K; Billia M; Mazzola CR; Williams A; Al-Zahrani A; Chin LKJ; Stokl A; Cnossen S; Mallick R; Lavallee LT; Morash C; Cagiannos I; Breau RH; Benidir T; Finelli A; Hamilton RJ; Hersey K; Joshua AM; Kulkarni GS; Zlotta A; Fleshner N; Cole-Clark D; Feletto E; Bang A; Chalasani V; Rasiah K; Smith D; Billia M; Siddiqui K; Goodman C; Mazzola CR; Izawa J; Chin LKJ; Billia M; Siddiqui K; Goodman C; Mazzola CR; Williams A; Chin LKJ; Saad F; Shore N; Smith MR; Lipton A; Brown JE; Oudard S; Carducci M; Damiao R; Zhu L; Warner D; Fizazi K; Saad F; Joshua AM; Beer TM; Armstrong A; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; DeBono J; Carles J; Mainwaring P; Evans CP; Parli T; Mansbach H; Bhattacharya S; Steve VO; Phung D; Tombal B; Venner P; Rocha J; Vanhuyse M; Aprikian A; Cury F; Kassouf W; Dragomir A; Dason SR; Allard CB; Hoogenes J; Orovan W; Shayegan B; Kroczak TJ; Awe JA; Saranchuk JW; Mai S; Drachenberg DE; Kaler K; Rittberg R; Patel P; Kroczak TJ; Saranchuk JW; Drachenberg DE; Bhindi B; Fleshner N; Kulkarni GS; Sutradhar R; Lipscombe L; Jembere N; Saskin R; Alibhai SM; Bhindi B; Hermanns T; Wei Y; Templeton A; Richard P; Bhatt J; Noon A; Jewett M; Hamilton RJ; Trachtenberg J; Finelli A; Fleshner N; Zlotta A; Kulkarni GS; O’Malley PG; Bashir AHAA; Nguyen DP; Wu G; Herman M; Christos P; Sanda MG; Thompson IM; Wei JT; Lee R; Rubin MA; Barbieri CE; Scherr DS; Patel P; Nayak JG; Biljetina Z; Donnelly BJ; Trpkov K; Lateef MA; Péant B; Astolfi M; Kendall-Dupont J; Mes-Masson A-M; Gervais T; Saad F; Huang CH; Bjazevic J; Nayak JG; Quon H; Drachenberg DE; Huang CH; Bjazevic J; Drachenberg DE; Molina OE; LaRue H; Picard V; Têtu B; Nguile-Makao M; Bergeron A; Fradet V; Campos-Lima PO; Lacombe L; Fradet Y; Lavallée E; Ben-Zvi T; Nguile-Makao M; Pelletier J-F; Allaire J; Léger C; Fradet Y; Fradet V; Benidir T; Bhindi B; Kulkarni GS; Finelli A; Hamilton RJ; Jewett M; Hersey K; Theodorus VDK; Evans A; Nesbitt M; Kalnin R; Alibhai S; Trachtenberg J; Fleshner N; Paterson NR; Nguyen LN; Lavallee LT; Witiuk K; Ross J; Mallick R; Shabana W; MacDonald B; Schieda N; Fergusson D; Momoli F; Cnossen S; Cagiannos I; Morash C; Breau RH; Mohammed A; Finelli A; Fleshner N; Winegarden N; Kulkarni GS; Matteliano AA; Kaler K; Drachenberg DE; Saranchuk JW; Alesawi A; Meskawi M; Benayoun S; Lebeau T; El-Hakim A; Alesawi A; Meskawi M; Benayoun S; Lebeau T; El-Hakim A; Marzouk K; Whelan TF; Hasan T; McBriarty H; Zimmermann M; Taussky D; Delouya G; Alenizi AM; Zorn KC; Taussky D; Bahig H; Delouya G; Nadiri A; Bodson-Clermont P; Soulière D; Toren PJ; Allman J; Gleave M; Zoubeidi A; Kang YH; Heo JH; Jin H; Park KC; Kim KH; Hong SJ; Han KS; Duplisea J; Merrimen J; Rendon RA; Feifer AH; Cafazzo J; Seto E; Hu J; Aprikian A; Cury F; Vanhuyse M; Dragomir A; Keefe DT; Flood TA; Breau RH; Cagiannos I; Morash C; Schieda N; Egerdie RB; Tammela T; Sieber P; Lamy O; Ke C; Warner D; Klotz L; Smith MR; Brown JE; Fizazi K; Marx G; Wang H; Warner D; Lipton A; Alhasani H; Salam MJ; Khadermand K; Farhad FK; Anwar A; Dryhurst D; Hammadeh M; Zang A; Ahmed M; Rajih E; Naif AH; Alenizi AM; El-Hakim A; Delouya G; Bahary J-P; Barkati M; Taussky D; Lambert L; Jutras A; Comeau D; Normandeau L; Decamps V; Lattouf J-B; Saad F; Drake MJ; Sokol R; Klaver M; Drogendijk T; Hakimi Z; Odeyemi I; Kerrebroeck V; Philip EV; Drake MJ; Oelke M; Traudtner K; van Charldorp K; Klaver M; Van Kerrebroeck PEV; Hosier GW; Himmelman JG; Tennankore KK; Cox AR; Liberman D; Goldfarb R; Fan Y; Elliott SP; Carlson K; Civitarese A; Weber BA; Crump T; Desantis D; Baverstock R; Wagg AS; Franks B; Ramos B; Berner T; Baverstock R; Civitarese A; Yanko D; Desantis D; Crump T; Carlson K; Azizi M; Hai MA; Gonzalez RR; Eure GR; Kriteman LS; Hueber P-A; Alenizi AM; Bienz M; El Hosni K; Meskawi M; Zorn KC; Tholomier C; Eure GR; Kriteman LS; Hai MA; Gonzalez RR; Zorn KC; Elkoushy M; Elshal A; Elhiali M; Elkoushy M; Elshal A; Elhiali M; Lusty AJ; Siemens DR; Drake MJ; Chapple CR; Oelke M; Drogendijk T; Klaver M; Van Kerrebroeck PEV; Baverstock R; Civitarese A; Weber BA; Desantis D; Crump T; Carlson K; Golda N; Nickel JC; Tripp D; Carr L; Herschorn S; Yassein A; Davies TO; Howlett M; Gibson W; Hunter KF; Chambers T; Wagg AS; Gibson W; Wagg AS; Baverstock R; Civitarese A; Weber BA; Desantis D; Crump T; Carlson K; Elkoushy M; Elshal A; Elhiali M; Lavigueur-Blouin H; Meskawi M; Valdivieso R; Hueber P-A; Trudeau V; Bienz M; Zorn KC; Valdivieso R; Hueber P-A; Meskawi M; Lavigueur-Blouin H; Alenizi AM; Misrai V; Rutman M; Te A; Chungtai B; Barber NJ; Emara AM; Trinh Q-D; Munver R; Zorn KC; Tholomier C; Eure GR; Kriteman LS; Hai MA; Gonzalez RR; Zorn KC; Hueber P-A; Bienz M; Valdivieso R; Misrai V; Rutman M; Te A; Chughtai B; Barber N; Munver R; Zorn KC; Hoy NY; Van Zyl S; St. Martin BA; Agrawal CS; Shah P; Agrawal S; Khanal B; Pandey AK; Shabana W; Dawod T; Telb M; Shahin A; Eladl M; Whoriskey M; Amir B; Cox AR; Quirouet A; Jones S; Bhattacharyya P; Goldman H; Nayak JG; Gore JL; Holt SK; Wright JL; Mossanen M; Dash A; Bhindi B; Hermanns T; Wei Y; Yu J; Templeton A; Noon A; Bhatt J; Richard P; Almatar A; Jewett M; Hamilton RJ; Finelli A; Fleshner N; Zlotta A; Kulkarni GS; Elzayat E; Cagiannos I; Lavallee LT; Cnossen S; Mallick R; Morash C; Breau RH; Siemens DR; MacKillop WJ; Peng Y; Doiron RC; Booth CM; Santos F; Dragomir A; Ahmed AS; Kassouf W; Aprikian A; Bureau M; Rousseau A; Pelletier J; Ringuette-Goulet C; Bernard G; Neveu B; Pouliot F; Bolduc S; Ahmed AS; Santos F; Kassouf W; Tanguay S; Aprikian A; Bos D; Allard CB; Dason SR; Ruzhynsky V; Kapoor A; Shayegan B; Bell M; Yafi FA; Brimo F; Steinberg J; Aprikian A; Tanguay S; Kassouf W; Allaire J; Nguile-Makao M; Léger C; Ben-Zvi T; Fradet Y; Lacombe L; Fradet V; Kinnaird A; Dromparis P; Evans H; Allard M-A; Allaire J; Nguile-Makao M; Léger C; Ben-Zvi T; Fradet Y; Lacombe L; Fradet V; Acker MR; Harb-De la Rosa A; Narayanan G; Manoharan M; Harb-De la Rosa A; Acker MR; Soodana-Prakash N; Balise RR; Parekh D; Manoharan M; Chung J; Kulkarni GS; Matthew A; Guttman D; Fraser I; Bender J; Abdelmutti N; Papadakos J; Jones J; Ben-Zvi T; Allaire J; Allard M-A; Leger C; Nguile-Makao M; Fradet Y; Lacombe L; Fradet V; Neufeld S; Kroczak TJ; Czaykowski P; Koul R; Aljada I; Ahmed S; Drachenberg DE; Nandwani GM; Anwar A; Addla SK; Singh R; Chahal R; Abou-Taleb AA; Noureldin Y; Almatar AA; Matta R; Hermanns T; Wei L; Yu J; Athanasopoulos P; Varghese B; Jewett M; Fleshner N; Zlotta A; Kulkarni GS; O’Malley PG; Al Hussein Al Awamlh B; Nguyen DP; Faltas B; Lee R; Scherr DS; Sanchez A; Rodriguez D; Allard CB; Bechis SK; Cheng J-S; Barrisford GW; Preston MA; Gelpi-Hammerschmidt F; Feldman AS; Nayan M; Jewett M; Anson-Cartwright L; Bedard P; Moore M; Chung P; Warde P; Sweet J; O’Malley M; Hamilton RJ; Nayan M; Jewett M; Bedard P; Hamilton RJ; Ko JJ; Asif T; Li H; Alimohamed N; Bassily D; Nguyen PT; Heng DYC; Punjani N; Power NE; Macleod LC; Nayak JG; Rajanahally S; Holt SK; Schade GR; Lin DW; Gore JL; Nayak JG; Holt SK; Wright JL; Dash A; Gore JL; Beech BB; Izawa J; Pautler SE; Chin LKJ; Power NE; Li J; Willie C; Lowerison M; Pautler SE; Izawa J; Lacefield J; Leong H; Power NE; Siddiqui K; Chan G; Wambolt E; Tangen-Steffin K; Goulart J; Leong H; Leong N; Chin LKJ; Juvet T; Bieniek J; Bachir BG; Margolis M; Grober ED; Lo K; Jarvi K; Abara E; Abara N; Lacroix M; Noushi N; Chiang S; Wu B; Denton R; Cameron R; Liberman D; Jarosek SL; Virnig BA; Elliott SP; Blais A-S; Bergeron M; Nadeau G; Bolduc S; Blais A-S; Nadeau G; Moore K; Genois L; Bolduc S; Keays MA; Snodgrass W; Starke N; Bernstein I; Lee SC; Corbin Bush N; Keays MA; Corbin Bush N; Snodgrass W; Sami S; Dhaliwal N; Fermin Risso C; Cook AJ; Weber BA; Sami S; Frusescu A; Fermin Risso C; Cook AJ; Weber BA; Huynh M; Dave S; Parikh N; Lee L; Lorenzo A; Odeh R; Bowlin P; Traubici J; Koyle M; Dave S; Wang P; Romagnoli C; Fenster A; Bolduc S; Fortin A; Morin V; Gervais P; Daugherty MR; Bratslavsky G; Riddell J; Alyami F; Bowlin P; Lee L; Braga LH; Koyle M; Lorenzo A; Alyami F; Alqarni N; Odeh R; Penna FJ; Lee L; Dos Santos J; Koyle M; Lorenzo A; Farhat WA; Alyami F; Bowlin P; Lee L; Gleason JM; Braga LH; Bagli DJ; Koyle M; Lorenzo A; Alyami F; Odeh R; Heidari Bateni Z; Farhat WA; Koyle M; Nguyen LN; Rediger C; Leonard M; Guerra L; Wehbi E; Dorgalli C; Hidas G; McLorie G; McAleer I; Selby B; Pribish M; Khoury AE; Wehbi E; Dorgalli C; Hidas G; McLorie G; McAleer I; Selby B; Pribish M; Khoury AE; Wehbi E; Walia A; Dorgalli C; Hidas G; McLorie G; McAleer I; Selby B; Pribish M; Khoury AE; Alqarni N; Odeh R; Butt H; Alkahtani M; Konstant L; Pandergast L; D’Arpino T; Koyle M; Pelletier J; Bolduc S; Moore K; Wilkes CG; Thibodeau BA; Metcalfe PD; Baltazar JAJ; D’Cruz J; Kim S; Rickard M; DeMaria JE; Braga LH; Penna FJ; Odeh R; Butt H; Lorenzo A; Farhat WA; Bagli DJ; Koyle M; Lee L; Gleason JM; Bowlin P; Alyami F; Penna FJ; Braga LH; Lorenzo A; Lobb I; Liu W; Carter D; Haig A; Lan Z; Sener A; Anderson P; McAlister VC; Sener A; Luke PP; Penna FJ; Lorenzo A; Butt H; Farhat WA; Koyle M; Lee L; Penna FJ; Harvey E; John P; Armstrong D; Luginbuehl I; Alyami F; Koyle M; Lorenzo A; Odeh R; Levine M; Schuler TD; Gourishankar S; Odeh R; Lorenzo A; Farhat WA; Alyami F; Jain A; Penna FJ; Butt H; Alqarni N; Koyle M; Gardiner C; Koulack J; McGregor TB; Rickard M; Brownrigg N; D’Cruz J; DeMaria JE; Braga LH; Luz MA; Mattana J; Ribeiro R; Luz MA; Mattana J; Ribeiro R; Alyami F; Bowlin P; Lee L; Farhat WA; Quirouet A; Abraham N; Goldman H; Shahrour W; Hunter CB; Suranah S; Batra V; Joshi PM; Kulkarni J; Sansalone S; Lazzeri M; Barbagli G; Kulkarni S; Almarzouq AN; Al-Yousef RJ; Aldousari S; Shahrour W; Joshi P; Hunter CB; Batra V; Suranah S; Kulkarni J; Kulkarni S, 2015, '2015 CUA Abstracts', Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 9, pp. S13 - S134

Journal articles | 2015

Puts M; Sattar S; McWatters K; Lee K; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Jang RW-J; Alibhai SMH, 2015, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', Journal of Clinical Oncology, 33, pp. TPS9634 - TPS9634,

Journal articles | 2015

Robert C; Joshua AM; Kefford R; Joseph RW; Wolchok JD; Hodi FS; Hamid O; Weber JS; Gangadhar TC; Dronca RS; Patnaik A; Zarour HM; Hwu W-J; Hersey P; Daud A; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Ribas A, 2015, 'Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.', Journal of Clinical Oncology, 33, pp. 9050 - 9050,

Journal articles | 2015

Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PFA; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE, 2015, 'Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study', The Lancet Oncology, 16, pp. 152 - 160,

Journal articles | 2015

Seah JA; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Knox JJ; Joshua AM; Sridhar SS, 2015, 'Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer', Clinical Genitourinary Cancer, 13, pp. e229 - e233,

Journal articles | 2015

Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN, 2015, 'A phase II study of GW786034 (Pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer', Clinical Genitourinary Cancer, 13, pp. 124 - 129,

Journal articles | 2015

Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF, 2015, 'Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy', British Journal of Cancer, 112, pp. 832 - 840,

Journal articles | 2014

Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DYC; Joshua AM; Chi KN, 2014, 'A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer', Prostate, 74, pp. 1544 - 1550,

Journal articles | 2014

Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; De Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B, 2014, 'Enzalutamide in metastatic prostate cancer before chemotherapy', New England Journal of Medicine, 371, pp. 424 - 433,

Journal articles | 2014

Bochner B; Sperling D; Feifer A; Mashni J; Bajorin D; Dalbagni G; Herr H; Donat SM; Milowsky M; Shah J; Kamat A; Grossman HB; Grubb R; Brandes S; Bullock A; Strope S; Roth B; Kibel A; Weigand L; Steinberg G; Stadler W; Rutiaga N; Schoenberg M; Bivalacqua T; Rogers C; Black P; So A; Gleave M; Kassouf W; Bachir B; Yafi F; Lerner S; Godoy G; Amiel G; Zlotta A; Fleshner N; Jewett M; Kulkarni G; Sridhar S; Tanock I; Joshua A; Bostrom P; Kuk C; Lotan Y, 2014, 'MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER', Journal of Urology, 191,

Journal articles | 2014

Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2014, 'Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial', JAMA, 311, pp. 2397 - 2405,

Journal articles | 2014

Gedye C; Hogg D; Butler M; Joshua AM, 2014, 'New treatments for metastatic melanoma', CMAJ. Canadian Medical Association Journal, 186, pp. 754 - 760,

Journal articles | 2014

Hansen A; Geddie W; Boerner S; Ghai S; Berman H; Serra S; Roehrl M; Joshua AM; Oza AM; Moore M; Amir E; Usmani T; Giesler A; Amin N; Zhang T; Sukhai M; Stockley T; Kamel-Reid S; Siu LL; Bedard P, 2014, 'Fine Needle Biopsies are Feasible As a Minimally Invasive Means for Targeted Next Generation Sequencing in Advanced Solid Tumors', Annals of Oncology, 25, pp. iv558 - iv558,

Journal articles | 2014

Hodi FS; Ribas A; Daud A; Hamid O; Robert C; Kefford R; Hwu W-J; Gangadhar TC; Joshua AM; Hersey P; Weber J; Joseph RW; Zarour H; Dronca R; Gammage L; Hille D; Xue D; Kang SP; Chun P; Ebbinghaus SW; Perrone A; Wolchok JD, 2014, 'Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)', Journal for immunotherapy of cancer, 2, pp. P103 - P103,

Journal articles | 2014

Joshua AM; Zannella VE; Downes MR; Bowes B; Hersey K; Koritzinsky M; Schwab M; Hofmann U; Evans A; Van Der Kwast T; Trachtenberg J; Finelli A; Fleshner N; Sweet J; Pollak M, 2014, 'A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer', Prostate Cancer and Prostatic Diseases, 17, pp. 252 - 258,

Journal articles | 2014

Khoja LT; Nguyen L; Wang L; Zhang B; Nie J; Yen PH; Pnaik M; Powis M; Franke N; Crump M; Hogg D; Joshua AM; Ohashie P; Butler MO, 2014, 'A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma', Annals of Oncology, 25, pp. iv391 - iv391,

Journal articles | 2014

Lebowitz-Amit R; Mete O; Asa SL; Ezzat S; Joshua AM, 2014, 'Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: A case report and literature review', Endocrine Practice, 20,

Journal articles | 2014

Leibowitz-Amit R; Alimohamed N; Vera-Badillo FE; Seah JA; Templeton AJ; Knox JJ; Tannock IF; Sridhar SS; Joshua AM, 2014, 'Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone', Prostate, 74, pp. 1462 - 1464,

Journal articles | 2014

Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM, 2014, 'Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole', European Journal of Cancer,

Journal articles | 2014

Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; De Bono JS; Joshua AM, 2014, 'Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer', Annals of Oncology, 25, pp. 657 - 662,

Journal articles | 2014

Puts M; Krzyzanowska M; Amir E; Joshua A; Monette J; Wan-Chow-Wah D; Jang R; Alibhai S, 2014, 'A feasibility trial of geriatric assessment and management for older cancer patients', Journal of Geriatric Oncology, 5, pp. S47 - S48,

Journal articles | 2014

Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Iannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).', Journal of Clinical Oncology, 32, pp. LBA9000 - LBA9000,

Journal articles | 2014

Robert C; Mateus C; Hodi S; Kefford R; Hamid O; Daud A; Wolchok J-D; Hwu W-J; Gangadhar T-C; Patnaik A; Joshua A-M; Hersey P; Weber J; Dronca R; Zarour H; Gergich K; Li X-N; Lannone R; Kang S-P; Ebbinghaus S; Ribas A, 2014, 'Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique', Annales de Dermatologie et de Vénéréologie, 141, pp. S258 - S259,

Journal articles | 2014

Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A, 2014, 'Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial', The Lancet, 384, pp. 1109 - 1117,

Journal articles | 2013

Alibhai S; Manokumar T; Aziz S; Rizvi F; Breunis H; Gulamhusein H; Timilshina N; Tannock I; Joshua A, 2013, 'Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer?', Journal of Geriatric Oncology, 4, pp. S37 - S37,

Journal articles | 2013

Authors V, 2013, 'Abstracts from the 33rd Annual Scientific Meeting of the Canadian Geriatrics Society Toronto, April 2013', Canadian Geriatrics Journal, 16, pp. 66 - 103,

Journal articles | 2013

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003,

Journal articles | 2013

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003,

Journal articles | 2013

Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A, 2013, 'Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma', New England Journal of Medicine, 369, pp. 134 - 144,

Journal articles | 2013

Hotte SJ; Eisenhauer EA; Joshua AM; Kumar V; Ellard S; Gregg RW; Macfarlane RJ; Winquist E; Torri V; Ruether JD; Basappa NS; Kakumanu AS; North SA; Kollmannsberger CK; Tinker A; Mirchandani D; Tassignon A; Hausman DF; Allan AL; Chi KN, 2013, 'NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. 5042 - 5042,

Journal articles | 2013

Joshua AM; Zannella VE; Downes MR; Bowes B; Koritzinsky M; Sweet J; Trachtenberg J; Jewett MAS; Finelli A; Fleshner NE; Pollak MN, 2013, 'Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.', Journal of Clinical Oncology, 31, pp. 5070 - 5070,

Journal articles | 2013

Leibowitz-Amit R; Joshua AM, 2013, 'The changing landscape in metastatic castration-resistant prostate cancer', Current Opinion in Supportive and Palliative Care, 7, pp. 243 - 248,

Journal articles | 2013

Leibowitz-Amit R; Templeton A; Alibhai S; Tannock I; Joshua AM, 2013, 'Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel', Journal of Geriatric Oncology, 4, pp. S34 - S34,

Journal articles | 2013

Leibowitz-Amit R; Templeton AJ; Atenafu EG; Vera-Badillo FE; Chllamma M; Solow HL; Knox JJ; Tannock I; Sridhar SS; Joshua AM, 2013, 'Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).', Journal of Clinical Oncology, 31, pp. 5058 - 5058,

Journal articles | 2013

Lun G; Atenafu EG; Knox JJ; Sridhar SS; Tannock IF; Joshua AM, 2013, 'Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: A pilot project at a canadian cancer center', Clinical Genitourinary Cancer, 11,

Journal articles | 2013

Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM; Tannock I; Alibhai SMH, 2013, 'A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.', Journal of Clinical Oncology, 31, pp. 9555 - 9555,

Journal articles | 2013

Margel D; Urbach DR; Lipscombe L; Bell C; Kilkarni G; Austin P; Joshua AM; Fleshner NE, 2013, 'Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men.', Journal of Clinical Oncology, 31, pp. 5007 - 5007,

Journal articles | 2013

Nguyen LT; Butler MO; Yen PH; Nie J; Pniak M; Elford AR; Joshua AM; Hogg D; Ghazarian D; Al-Habeeb A; Easson AM; Leong WL; McCready DR; Reedijk M; Messner HA; Ohashi PS, 2013, 'Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy', Journal for immunotherapy of cancer, 1, pp. P25 - P25,

Journal articles | 2013

Niraula S; Pond G; de Wit R; Eisenberger M; Tannock IF; Joshua AM, 2013, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study', Journal of the Canadian Urological Association, 7,

Journal articles | 2013

Pra AD; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; Van Der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG, 2013, 'TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: Implications for fusion status anddsb repair', Clinical Cancer Research, 19, pp. 5202 - 5209,

Journal articles | 2013

Ribas A; Robert C; Daud A; Hodi FS; Wolchok JD; Kefford R; Patnaik A; Hwu W-J; Weber JS; Joshua A; Hersey P; Gangadhar TC; Joseph RW; Dronca RS; Zarour HM; Ebbinghaus S; Gergich K; Li XN; Kang SP; Hamid O, 2013, 'Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.', Journal of Clinical Oncology, 31, pp. 9009 - 9009,

Journal articles | 2013

Richter S; Ruether JD; Wood L; Canil C; Moretto P; Venner P; Gingerich J; Emmenegger U; Eisen A; Zalewski P; Joshua A; Mukherjee SD; Heng D; Czaykowski P; Soulieres D; Blais N; Rendon R; Fleshner N; Crook JM; Sridhar SS, 2013, 'Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)', CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 7, pp. E797 - E811,

Journal articles | 2013

Ryan C; Smith M; de Bono J; Molina A; Logothetis D; De Souza P; et A, 2013, 'Abiraterone in metastatic prostate cancer without previous chemotherapy', New England Journal of Medicine, 368, pp. 138 - 148,

Journal articles | 2013

Templeton AJ; Vera-Badillo FE; Wang L; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore M; Sridhar SS; Joshua AM; Pond GR; Amir E; Tannock IF, 2013, 'Translating clinical trials to clinical practice: Outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials', Annals of Oncology, 24, pp. 2972 - 2977,

Journal articles | 2013

Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ, 2013, 'PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade', Modern Pathology, 26, pp. 435 - 447,

Journal articles | 2012

Chi K; Yu EY; Ellard S; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME, 2012, 'A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)', Annals of Oncology, 23, pp. ix297 - ix297,

Journal articles | 2012

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 30, pp. 4514 - 4514,

Journal articles | 2012

Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM, 2012, 'Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers', BJU International, 110, pp. 840 - 845,

Journal articles | 2012

Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG, 2012, 'PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy', Clinical Cancer Research, 18, pp. 1015 - 1027,

Journal articles | 2012

Joshua AM; Evren S; Zannella VE; Bowes B; Fleshner NE; Jewett MAS; Finelli A; Evans A; Koritzinsky M; Sweet J; Pollak MN, 2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', Journal of Clinical Oncology, 30, pp. e15118 - e15118,

Journal articles | 2012

Joshua AM; Fleshner N; Pollak M; Zannella V; Bowes B; Koritzinsky M; Sweet J; Evans A; Trachtenberg J; Jewett M; Finelli A, 2012, 'Abstract A15: A phase 2 study of neoadjuvant metformin in prostatic carcinoma', Cancer Research, 72, pp. A15 - A15,

Journal articles | 2012

Joshua AM, 2012, 'Melanoma prevention: Are we doing enough? A Canadian perspective', Current Oncology, 19,

Journal articles | 2012

Leibowitz–amit R; Joshua AM, 2012, 'Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions', Current Oncology, 19, pp. 22 - 31,

Journal articles | 2012

Montgomery RB; Joshua A; Hannah AL; Peterson AC; Lopez C; Gleave ME; Taplin M-E, 2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.', Journal of Clinical Oncology, 30, pp. TPS4695 - TPS4695,

Journal articles | 2012

Morin E; Mete O; Wasserman JD; Joshua AM; Asa SL; Ezzat S, 2012, 'Carney complex with adrenal cortical carcinoma', Journal of Clinical Endocrinology and Metabolism, 97,

Journal articles | 2012

Niraula S; Chi K; Joshua AM, 2012, 'Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer', Hormones and Cancer, 3, pp. 3 - 13,

Journal articles | 2012

Scher HI; Fizazi K; Saad F; Taplin M-E; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Flechon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS, 2012, 'Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy', NEW ENGLAND JOURNAL OF MEDICINE, 367, pp. 1187 - 1197,

Journal articles | 2011

Joshua A; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, '133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION', Journal of Urology, 185,

Journal articles | 2011

Joshua AM; Shen E; Yoshimoto M; Marrano P; Zielenska M; Evans AJ; Van Der Kwast T; Squire JA, 2011, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Prostate, 71, pp. 778 - 790,

Journal articles | 2011

Squire JA; Park PC; Yoshimoto M; Alami J; Williams JL; Evans A; Joshua AM, 2011, 'Prostate Cancer as a Model System for Genetic Diversity in Tumors', , 112, pp. 183 - 216,

Journal articles | 2010

Chung C; Dawson LA; Joshua AM; Brade AM, 2010, 'Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: Sunitinib and sorafenib', Anti-Cancer Drugs, 21, pp. 206 - 209,

Journal articles | 2010

Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS, 2010, 'Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)', PLoS ONE, 5,

Journal articles | 2010

Sahi C; Knox JJ; Clemons M; Joshua AM; Broom R, 2010, 'Renal cell carcinoma bone metastases: Clinical advances', Therapeutic Advances in Medical Oncology, 2, pp. 75 - 83,

Journal articles | 2009

Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ, 2009, 'Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma', Journal of Clinical Endocrinology and Metabolism, 94, pp. 5 - 9,

Journal articles | 2009

Joshua AM; Marrano P; Evans A; Van der Kwast T; Zielenska M; Squire J, 2009, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Journal of Clinical Oncology, 27, pp. 11107 - 11107,

Journal articles | 2009

Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB, 2009, 'Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer', Journal of Clinical Oncology, 27, pp. 6229 - 6236,

Journal articles | 2008

Joshua AM; Boutros PC, 2008, 'Web-based resources for clinical bioinformatics.', Methods in molecular medicine, 141, pp. 309 - 329,

Journal articles | 2008

Joshua AM; Evans A; Van der Kwast T; Zielenska M; Meeker AK; Chinnaiyan A; Squire JA, 2008, 'Prostatic preneoplasia and beyond', Biochimica et Biophysica Acta - Reviews on Cancer, 1785, pp. 156 - 181,

Journal articles | 2008

Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA, 2008, 'Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome', Modern Pathology, 21, pp. 1451 - 1460,

Journal articles | 2007

Joshua A; Vukovic B; Braude I; Fleshner NE; Hussein S; Srigley J; Evans A; Zielenska M; Squire J, 2007, '654: Telomere Length Analysis of High-Grade Prostatic Intrapeithelial Neoplasia and Surrounding Stroma Predicts Outcome to Prostate Cancer', Journal of Urology, 177, pp. 220 - 220,

Journal articles | 2007

Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley J; Evans A; Squire JA, 2007, 'Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer', Neoplasia, 9, pp. 81 - 89,

Journal articles | 2006

Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SRC; Petrilli AS; Andrade JAD; Chilton-MacNeill S; Zielenska M; Squire JA, 2006, 'Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma', BMC Cancer, 6,

Journal articles | 2006

Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis', Journal of Clinical Oncology, 24, pp. 10021 - 10021,

Journal articles | 2006

Nordman IC; Iyer S; Joshua AM; Clarke SJ, 2006, 'Advances in the adjuvant treatment of colorectal cancer', ANZ Journal of Surgery, 76, pp. 373 - 380,

Journal articles | 2006

Yoshimoto M; Cutz JC; Nuin PAS; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA, 2006, 'Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias', Cancer Genetics and Cytogenetics, 169, pp. 128 - 137,

Journal articles | 2006

Yoshimoto M; Joshua AM; Chilton-MacNeill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA, 2006, 'Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement', Neoplasia, 8, pp. 465 - 469,

Journal articles | 2006

Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer', Journal of Clinical Oncology, 24, pp. 10029 - 10029,

Journal articles | 2005

BURGE ME; JOSHUA AM; McNEIL CM; HUI R; BOYER MJ; ABRAHAM R, 2005, 'Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian ‘Special Access Scheme’ experience', Asia-Pacific Journal of Clinical Oncology, 1, pp. 47 - 52,

Journal articles | 2005

Joshua AM; Adams D; McKenzie P; Solomon M; Clarke SJ, 2005, 'Small blue cell tumors of the rectum: CASE 2. Small-cell carcinoma of the rectum', Journal of Clinical Oncology, 23, pp. 912 - 913,

Journal articles | 2005

Joshua AM; Boyer MJ; Subramanian R; Clarke SJ, 2005, 'Smoking reduction does work: Resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years', Respirology, 10, pp. 233 - 238,

Journal articles | 2005

Joshua AM; Celermajer DS; Stockler MR, 2005, 'Beauty is in the eye of the examiner: Reaching agreement about physical signs and their value', Internal Medicine Journal, 35, pp. 178 - 187,

Journal articles | 2005

Joshua AM; Cotroneo A; Clarke S, 2005, 'Humor and oncology', Journal of Clinical Oncology, 23, pp. 645 - 648,

Journal articles | 2005

Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer M, 2005, 'Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer', Internal Medicine Journal, 35, pp. 468 - 472,

Journal articles | 2005

Joshua AM; Nordman I; Venkataswaran R; Stockler M; Boyer M; Clarke S, 2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC)', Journal of Clinical Oncology, 23, pp. 4713 - 4713,

Journal articles | 2005

Millward MJ; Joshua A; Kefford R; Aamdal S; Thomson D; Hersey P; Toner G; Lynch K, 2005, 'Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma', Investigational New Drugs, 23, pp. 253 - 256,

Journal articles | 2005

Vardy J; Joshua AM; Clarke SJ; Yarrow PM; Lin BPC, 2005, 'Small blue cell tumors of the rectum: CASE 1. Erwing's sarcoma of the rectum', Journal of Clinical Oncology, 23, pp. 910 - 912,

Journal articles | 2004

Joshua AM; Burge ME; McNeil CM; Hui R; Boyer MJ; Abraham R, 2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285,

Journal articles | 2004

Joshua AM; Burge ME; McNeil CM; Hui R; Boyer MJ; Abraham R, 2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285,

Journal articles | 2004

Joshua AM; Carter JR; Beale P, 2004, 'The use of taxanes in choriocarcinoma; a case report and review of the literature', Gynecologic Oncology, 94, pp. 581 - 583,

Journal articles | 2004

Joshua AM; Stockler MR; Boyer MJ, 2004, 'Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma [1]', Internal Medicine Journal, 34, pp. 70 - 71,

Journal articles | 1997

Bennett S; Joshua A; Russell PJ, 1997, 'Reliable method of isolating transfected clones from the LNCaP human prostatic cell line', BioTechniques, 23, pp. 66 - 70,

Journal articles | 1997

Bennett S; Unknown ; Russell PJ, 1997, 'Isolation of transfected clones from the LNCaP human prostatic cell line', BioTechniques, pp. 66 - 68
Preprints | 2024

Apostolov E; Roden DL; Holliday H; Cazet A; Harvey K; Zhang H; Wu SZ; van der Leij S; Selth LA; Bartonicek N; Al-Eryani G; He M; Lundeberg J; Reeves J; Kench JG; Potter AJ; Stricker P; Joshua AM; Horvath L; Swarbrick A, 2024, Profiling of epithelial functional states and fibroblast phenotypes in hormone therapy-naïve localised prostate cancer,

Conference Papers | 2024

Gillessen S; Turco F; Davis ID; Efstathiou JA; Fizazi K; James ND; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Zilli T; Agarwal N; Antonarakis ES; Aparicio A; Armstrong AJ; Bastos DA; Attard G; Axcrona K; Ayadi M; Beltran H; Bjartell A; Blanchard P; Bourlon MT; Briganti A; Bulbul M; Buttigliero C; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Clarke CS; Clarke N; de Bono JS; De Santis M; Duran I; Efstathiou E; Ekeke ON; El Nahas TIH; Emmett L; Fanti S; Fatiregun OA; Feng FY; Fong PCC; Fonteyne V; Fossati N; George DJ; Gleave ME; Gravis G; Halabi S; Heinrich D; Herrmann K; Hofman MS; Hope TA; Horvath LG; Hussain MHA; Jereczek-Fossa BA; Jones RJ; Joshua AM; Kanesvaran R; Keizman D; Khauli RB; Kramer G; Loeb S; Mahal BA; Maluf FC; Mateo J; Matheson D; Matikainen MP; McDermott R; McKay RR; Mehra N; Merseburger AS; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Mutambirwa SBA; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Renard-Penna R; Ryan CJ; Saad F; Sade JP; Sandhu S; Sartor OA; Schaeffer E; Scher HI, 2024, 'Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)', in European Urology,

Other | 2024

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Data from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer,

Other | 2024

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Data from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer,

Other | 2024

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer,

Other | 2024

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Perez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2024, Supplementary Data 1 from A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, FIGURE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, Supplementary Data from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2024

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau H-T; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; Doger de Spéville B, 2024, TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Other | 2023

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang K-C; Poon V; Sutaria DS; Gurney H, 2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer,

Conference Abstracts | 2022

Aggarwal N; Parmar J; Zdanska O; Yousif J; Hurwitz J; Handel E; Prawira A; Joshua A; Cosman R; Liu JJ, 2022, 'Impact of Covid-19 on early phase clinical trials recruitment and treatment in a major metropolitan phase 1 unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 33 - 34,

Conference Abstracts | 2022

Allen IA; Russell A; Jackson KJ; Peters T; Gibson G; Joshua AM; Goodnow CC; Burnett DL; Barnet MB, 2022, 'Abstract 665: Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. 665 - 665,

Conference Papers | 2022

Allen IA; Russell A; Jackson KJ; Peters T; Gibson G; Joshua AM; Goodnow CC; Burnett DL; Barnet MB, 2022, 'Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022,

Conference Abstracts | 2022

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu SK; Joshua AM; Zhang AY; Francis RJ; Scott AM; Azad A; McJannett MM; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Preprints | 2022

Choi WY; Sánchez C; Li JJ; Dinarvand M; Adomat H; Ghaffari M; Khoja L; Vafaee F; Joshua AM; Chi KN; Guns EST; Hosseini-Beheshti E, 2022, Extracellular vesicles from biological fluids as potential biomarkers for prostate cancer, ,

Conference Abstracts | 2022

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4537 - 4537,

Conference Abstracts | 2022

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

De Bono JS; Joshua AM; Shore ND; Kramer G; Li XT; Poehlein CH; Schloss C; Yu EY, 2022, 'KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS218 - TPS218,

Conference Abstracts | 2022

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Ferrario C; Piulats JM; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PCC; Berry WR; Emmenegger U; Mourey L; Mar N; Appleman LJ; Joshua AM; Conter HJ; Li XT; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2022, 'Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 118 - 118,

Conference Abstracts | 2022

Fleshner NE; Hansen AR; Chin J; Winquist E; Van der Kwast T; Lajkosz K; Kenk M; Berlin D; Veloso R; Sridhar SS; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Joshua AM, 2022, 'Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027,

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Handel E; Leslie C; Ardolino L; Di Ciaccio PR; Grimison P; Ben T; Honeyball F; Lewin J; Viiala N; Murphy C; Milliken S; Bilmon I; Marx G; Gangatharan S; Hamid A; Zhang A; Hamad N; McCarthy L; Joshua AM; Barnet M, 2022, 'Descriptive analysis of bleomycin induced lung injury in a cohort of patients with germ cell tumours and Hodgkin's lymphoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 37 - 37,

Conference Abstracts | 2022

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000,

Conference Abstracts | 2022

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Jones RH; Pinato DJ; Joshua A; Forster MD; Morton C; Aboud K; Liu JJ; Fulgenzi C; Kefas J; Edmondson S; Main NJ; Paull JRA; Fairley JK; Spicer J, 2022, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1186 - S1187, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022,

Conference Abstracts | 2022

Kramer G; Shore ND; Joshua AM; Li XT; Poehlein CH; Schloss C; De Bono JS; Yu EY, 2022, 'KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS215 - TPS215,

Conference Abstracts | 2022

Mak B; Lin H-M; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang AY; Scheinberg T; Wittert G; Butler L; Hoy A; Meikle P; Horvath L, 2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Parmar J; Aggarwal N; Zdanska O; Yousif J; Hurwitz J; Handel E; Rodrigues A; Prawira A; Joshua A; Cosman R; Liu J, 2022, 'Telehealth maintains access to early phase clinical trials during the Covid-19 pandemic', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 154 - 155,

Conference Abstracts | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Pham J; Star P; Phan K; Loh Y; Joshua AM; Smith A, 2022, 'BRAF inhibition and the spectrum of Granulomatous Reactions', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, Vol. 63, pp. 106 - 106,

Conference Abstracts | 2022

Pook DW; Geynisman DM; Carles J; De Braud FG; Joshua AM; Perez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve MA; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund S; Harris A; Huang K-C; Sutaria DS; Gurney H, 2022, 'A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 95 - 95,

Conference Abstracts | 2022

Sacco JJ; Orloff MM; Patel SP; Conway M; Lim L-A; Fog LS; Sia D; McKenzie J; Mckay D; O'day R; Isaacs T; Shoushtari AN; Sullivan RJ; Kin S; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2022, 'Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40,

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022,

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017,

Conference Abstracts | 2022

Shore ND; De Bono JS; Kramer G; Joshua AM; Li XT; Poehlein CH; Schloss C; Yu EY, 2022, 'KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS204 - TPS204,

Preprints | 2022

Thavaneswaran S; Lin FP; Kansara M; Grady JP; Espinoza D; Joshua AM; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, 2022, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers,

Conference Abstracts | 2022

Todenhoefer T; Piulats JM; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Fong PCC; Berry WR; Emmenegger U; Mourey L; Mar N; Appleman LJ; Joshua AM; Conter HJ; Li XT; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2022, 'KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S789 - S790,

Conference Papers | 2022

Sacco JJ; Orloff MM; Patel SP; Conway M; Lim L-A; Fog LS; Sia D; McKenzie J; Mckay D; O'day R; Isaacs T; Shoushtari AN; Sullivan RJ; Kin S; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2022, 'Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS,

Conference Papers | 2021

Ardolino L; Joshua A; Horvath L; Mahon K; Mak B; Fizazi K; Sommer GS; Carles J; Sim H-W, 2021, 'The influence of concurrent lipid modifying medications in men receiving docetaxel or cabazitaxel for mCRPC - A meta-analysis of the FIRSTANA, PROSELICA, TAX-327 and TROPIC studies', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 68 - 69,

Conference Abstracts | 2021

Azad A; Dhiantravan N; Emmett L; Joshua AM; Vela I; Pattison DA; Francis RJ; Williams S; Sandhu SK; Davis ID; Neha N; Bressel M; Murphy DG; Hofman MS, 2021, 'UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Abstracts | 2021

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Abstracts | 2021

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2021, 'UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Papers | 2021

Hofman M; Emmett L; Iravani A; Sandhu S; Joshua A; Pattison D; Goh J; Kirkwood I; Tan TH; Francis R; Ng S; Rutherford N; Gedye C; Scott A; Lee S-T; Weickhardt A; Ramdave S; Kwan E; Azad A; Macdonald W; Redfern A; Zhang A; Stockler M; Martin A; Davis I, 2021, 'Lu-177-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, ELECTR NETWORK, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), ELECTR NETWORK, 12 June 2021 - 15 June 2021,

Conference Abstracts | 2021

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Abstracts | 2021

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Abstracts | 2021

Lin H-M; Mak B; Huynh K; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Du P; Yu J; Jia S; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021,

Conference Papers | 2021

Mak B; Lin H-M; Kwan E; Fettke H; Tran B; Davis I; Mahon K; Stockler M; Briscoe K; Marx G; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua A; Kohli M; Meikle P; Azad A; Horvath L, 2021, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 48 - 49,

Conference Abstracts | 2021

Mak B; Lin H-M; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Kohli M; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021,

Conference Abstracts | 2021

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39,

Conference Papers | 2021

Piperno-Neumann S; Hassel JC; Rutkowski P; Baurain J-F; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Nathan P, 2021, 'Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002,

Conference Abstracts | 2021

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021,

Conference Papers | 2021

Shenderov E; Mallesara GHG; Wysocki PJ; Xu W; Ramlau R; Weickhardt AJ; Zolnierek J; Spira A; Joshua AM; Powderly J; Antonarakis ES; Jang S; Aragon-Ching J; Shen J; Paller C; Vogelzang NJ; Leu K; Cortes J; Bohac C; Lugowska I, 2021, 'MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion', in ANNALS OF ONCOLOGY, ELSEVIER, pp. S657 - U246,

Preprints | 2021

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, 2021, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program,

Conference Papers | 2020

Alibhai SMH; Breunis H; Timilshina N; Hansen AR; Joshua AM; Warde PR; Gregg RW; Fleshner NE; Tomlinson G; Hotte SJ; Emmenegger U, 2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020,

Conference Papers | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020,

Conference Papers | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020,

Conference Abstracts | 2020

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Morris MF; Begbie S; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2020, 'UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020,

Conference Abstracts | 2020

Herrera-Caceres* J; Joshua A; Sweet J; Chin J; Hansen A; Hamilton R; Sridhar S; Finelli A; Zlotta A; Fleshner N; Winquist E, 2020, 'MP67-12 ANTI-ANDROGENS AND CABAZITAXEL IN DEFINING COMPLETE RESPONSE IN PROSTATECTOMY (ACDC TRIAL) (ACDC-RP)', in Journal of Urology, Ovid Technologies (Wolters Kluwer Health), Vol. 203,

Conference Papers | 2020

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020,

Conference Papers | 2020

Jamal S; Nagrial A; Joshua A; Eek R; Jamal S, 2020, 'PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A480 - A481,

Conference Abstracts | 2020

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020,

Conference Abstracts | 2020

Kolinsky MP; Gravis G; Mourey L; Piulats JM; Sridhar SS; Romano E; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; De Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Schloss C; Poehlein CH; Yu EY, 2020, 'KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020,

Conference Abstracts | 2020

Kolinsky MP; Gravis G; Mourey L; Piulats JM; Sridhar SS; Romano E; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; De Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Schloss C; Poehlein CH; Yu EY, 2020, 'KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 103 - 103,

Conference Abstracts | 2020

Madariaga A; Marastoni S; Colombo I; Mandilaras V; Cabanero M; Bruce J; Garg S; Wang L; Gill S; Dhani NC; Bowering V; Li X; Oza AM; Joshua AM; Lheureux S, 2020, 'Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020,

Conference Abstracts | 2020

Madariaga A; Marastoni S; Colombo I; Mandilaras V; Cabanero M; Bruce J; Garg S; Wang L; Gill S; Dhani NC; Bowering V; Li X; Oza AM; Joshua AM; Lheureux S, 2020, 'Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 6049 - 6049,

Conference Posters | 2020

Maio M; Carlino M; Joshua A; McWhirter E; Ribas A; Ascierto P; Miller W; Butler M; Ferrucci P; Zielinski R; Vecchio MD; Gasal E; Ghori R; Diede S; Croydon E; Hamid O, 2020, 'P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma', pp. A10.2 - A11, presented at 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): late breaking abstracts,

Conference Papers | 2020

Marastoni S; Pesic A; Nair SN; Li ZJ; Madani A; Haibe-Kains B; Wouters BG; Joshua A, 2020, 'Targeting lysosomal homeostasis in ovarian cancer through drug repurposing', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020,

Preprints | 2020

Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B, 2020, Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment,

Conference Papers | 2020

Schmidt AL; Anton A; Wong SS; Azad A; Kwan EM; Spain LA; Torres J; Muthusamy A; Parente P; Parnis F; Goh JC; Joshua AM; Pook DW; Gibbs P; Tran B; Weickhardt AJ, 2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020,

Conference Abstracts | 2019

Alibhai SMH; Breunis H; Gregg RW; Hansen AR; Warde PR; Timilshina N; Tomlinson G; Joshua AM; Fleshner NE; Emmenegger U, 2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019,

Conference Abstracts | 2019

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115,

Conference Papers | 2019

Barnet M; Pathmanandavel S; McCarthy L; Goodnow C; Joshua A, 2019, 'The Australian Exceptional Responders Program: A national collaboration', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019,

Conference Abstracts | 2019

Chen J; Joshua AM; Denmeade SR; Antonarakis ES; Crumbaker M, 2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019,

Conference Abstracts | 2019

Emmett L; Chalasani V; Kneebone A; Hruby G; Joshua AM, 2019, 'Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade.', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, ITALY, Milan, Vol. 133, pp. S445 - S446, presented at 38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), ITALY, Milan, 26 April 2019 - 30 April 2019,

Conference Abstracts | 2019

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019,

Conference Abstracts | 2019

Fong PCC; Retz M; Drakaki A; Massard C; Berry WR; Romano E; De Bono JS; Feyerabend S; Appleman LJ; Conter HJ; Sridhar SS; Shore ND; Linch MD; Joshua A; Gurney H; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019,

Conference Papers | 2019

Gurney H; Massard C; Retz M; Tafreshi A; Carles J; Hammerer P; Fong PCC; Shore ND; Joshua AM; Linch MD; Romano E; Augustin M; Piulats J; Quevedo F; Berry WR; Kolinsky MP; Sridhar SS; Conter HJ; Drakaki A; Feyerabend S; Appleman LJ; Wu H; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2019, 'List of Poster Abstracts', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 31 - 32,

Conference Abstracts | 2019

Herrera-Caceres JO; Goldberg H; Hansen AR; Sridhar SS; Hamilton RJ; Finelli A; Zlotta A; Joshua AM; Fleshner NE, 2019, 'Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019,

Conference Abstracts | 2019

Jiang DM; Fallah-Rad N; Lee R; Ng P; Smith AD; Hansen AR; Joshua AM; Sridhar SS, 2019, 'Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019,

Conference Abstracts | 2019

Mak B; Mahon KL; Stockler MR; Joshua AM; Zhang AY; Parnis F; Meikle P; Horvath L, 2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019,

Conference Abstracts | 2019

Massard C; Retz M; Hammerer P; Quevedo F; Fong PCC; Berry WR; Gurney H; Piulats JM; Joshua A; Linch MD; Kolinsky M; Romano E; Sridhar SS; Conter HJ; Augustin M; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019,

Conference Abstracts | 2019

Millward M; Gan HK; Joshua AM; Kuo JC-Y; Prawira A; Richardson GE; Barbee SD; Inamdar SP; Pierce KL; Qureshi M; Horvath L, 2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019,

Conference Abstracts | 2019

Rose AAN; Armstrong SM; Hogg D; Butler M; Joshua AM; Ghazarian D; Kamel-Reid S; Al Habeeb A; Chappell MA; Ross K; Amir E; Bedard PL; Siu L; Spreafico A, 2019, 'The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019,

Conference Papers | 2019

Rose AAN; Armstrong SM; Hogg D; Butler M; Joshua AM; Ghazarian D; Kamel-Reid S; Habeeb AA; Chappell MA; Ross K; Amir E; Bedard PL; Siu L; Spreafico A, 2019, 'Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, pp. 3141 - 3141, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA,

Conference Papers | 2019

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2019, 'Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 64,

Conference Abstracts | 2019

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019,

Conference Papers | 2018

Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P, 2018, 'Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)', in Journal of Clinical Oncology, pp. 1232 - 1239,

Conference Papers | 2018

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of Lu-177-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY,

Conference Papers | 2018

Emmett L; Joshua A; Epstein R; Chalasani V; Kneebone A; Hruby G; O'Neill G; Stricker P; Stricker P; Quoc N; Ho B, 2018, 'Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), PA, Philadelphia, 23 June 2018 - 26 June 2018,

Conference Abstracts | 2018

Kanjanapan Y; Day D; Wang L; Hansen AR; Razak ARA; Spreafico A; Leighl NB; Joshua AM; Butler MO; Hogg D; Siu LL; Bedard PL, 2018, 'Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 36,

Conference Abstracts | 2018

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147,

Conference Posters | 2017

Hess D; Sebastian LT; Sjoquist KM; Lee CK; Hague W; Miller D; Cowley M; Qiu MR; Fox SB; Joshua AM; Simes J; Thomas DM, 2017, 'The Molecular Screening and Therapeutics (MoST) Program: A precision medicine framework for biomarker-driven signal seeking clinical studies for rare cancers.', IL, Chicago, Vol. 35, presented at 53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017,

Conference Posters | 2017

Joshua AM; Fleshner NE; Chin J; Emmenegger U; Gleave ME; Hotte SJ; Sweet J; Collins C; Boutros PC; Lupien M; Pugh TJ; Chi KN, 2017, 'Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017,

Conference Posters | 2017

Joshua AM; Stricker P; Epstein RJ; Ho B; Quoc N; Kent R; Willowson KP; Hofman M; Violet JA; Emmett L, 2017, 'Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of Lu-177 DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017,

Conference Abstracts | 2017

Kanjanapan Y; Day D; Butler M; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell MA; Chow K; Paolo M; Sherwin B; Stayner L-A; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2017, 'Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017,

Conference Abstracts | 2017

Khoja L; Atenafu E; Joshua AM, 2017, 'Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017,

Conference Abstracts | 2017

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017,

Conference Posters | 2016

Bavi P; Kiehl R; Adeyi O; Mete O; Avila-Casado C; Sharifzad H; Joshua A; Butany J; Roehrl MH, 2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Posters | 2016

Bavi P; Kiehl R; Adeyi O; Mete O; Avila-Casado C; Sharifzad H; Joshua A; Butany J; Roehrl MH, 2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Posters | 2016

Bavi P; Sharifzad H; Butany J; Joshua A; Roehrl MH, 2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Posters | 2016

Bavi P; Sharifzad H; Butany J; Joshua A; Roehrl MH, 2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Posters | 2016

Bavi P; Sharifzad H; Yang Q; Oldfield L; Joshua A; Butany J; Roehrl MH, 2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 29, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Posters | 2016

Bavi P; Sharifzad H; Yang Q; Oldfield L; Joshua A; Butany J; Roehrl MH, 2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 96, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016,

Conference Papers | 2016

Corfield J; Crozier J; Joshua A; Bolton D; Lawrentschuk N, 2016, 'Understanding the role of new systemic agents in the treatment of prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 12 - 12, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016,

Conference Posters | 2016

Day D; Joshua AM; Wang L; Razak AR; Hansen AR; Leighl NB; Butler MO; Spreafico A; Siu LL; Bedard PL, 2016, 'Development of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI): A novel prognostic score for patients (pts) treated in immune oncology (IO) phase I (P1) trials', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016,

Conference Papers | 2016

Ernst DS; Petrella T; Joshua A; Cheng T; Smylie M; Baetz T; Hamou A; Gwadry-Sridhar F, 2016, 'Impact of ipilimumab on metastatic melanoma: Evaluation using patient registry in Canada', in Annals of Oncology, pp. vi384,

Conference Posters | 2016

Fallah-Rad N; Bedard PL; Siu LL; Serra S; Kamel-Reid S; Butler MO; Joshua AM; Yu C; Chow H; Zhang W; Knox JJ; Krzyzanowska MK; Liu G; Jang RW-J; Razak ARA; Chen EX, 2016, 'IDH-1/2mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016,

Conference Posters | 2016

Hansen A; Tannock I; Templeton AJ; Prawira A; Knox J; Vera-Badillo F; Chen E; Zavitz MB; Wang L; Evans A; Tan Q; Wouters B; Sridhar S; Joshua A, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)', Vol. 27, pp. vi249,

Conference Posters | 2016

Hansen AR; Tannock I; Prawira A; Knox JJ; Templeton AJ; Vera-Badillo F; Chen EX; Zavitz M-B; Wang L; Evans A; Tan S; Wouters B; Sridhar SS; Joshua AM, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016,

Conference Papers | 2016

Manders P; Joshua AM; Kefford R; Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Hersey P; Li XN; Diede SJ; Ebbinghaus S; Hodi FS, 2016, 'THREE-YEAR OVERALL SURVIVAL FOR PATIENTS WITH ADVANCED MELANOMA TREATED WITH PEMBROLIZUMAB IN KEYNOTE-001', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 47 - 48,

Conference Posters | 2016

Puts M; Sattar S; Macdonald ME; Kulik M; McWatters K; Lee K; Amir E; Jang RW-J; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Alibhai SMH, 2016, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016,

Conference Posters | 2016

Puts M; Sattar S; McWatters K; Lee K; Kulik M; Macdonald ME; Jang RW-J; Amir E; Krzyzanowska MK; Leighl NB; Fitch M; Joshua AM; Warde PR; Tourangeau A; Alibhai SMH, 2016, 'What is the role of comorbidity, frailty, and functional status in the decision-making process for older adults with cancer and their family members, oncologists, and family physician?', CA, San Francisco, Vol. 34, presented at Cancer Survivorship Symposium on Advancing Care and Research, CA, San Francisco, 15 January 2016 - 16 January 2016,

Conference Papers | 2016

Samadian S; Bavi P; Chadwick D; Danesh A; Dowar M; Li T; Siva M; Roehl M; Joshua AM; Pugh TJ, 2016, 'Abstract 167: Inferring subclonal relationships between multiple metastases from rapid autopsy of a single melanoma patient', in Cancer Research, American Association for Cancer Research (AACR), pp. 167 - 167,

Conference Posters | 2016

Smith AD; Truong M; Bristow R; Wouters B; Milosevic MF; Joshua AM, 2016, 'The utility of serum CA9 in prognostication in prostate cancer', CA, San Francisco, Vol. 34, presented at Genitourinary Cancers Symposium, CA, San Francisco, 07 January 2016 - 09 January 2016,

Conference Posters | 2016

Todenhfer T; Azad A; Stewart C; Gao J; Eigl BJ; Black PC; Joshua AM; Chi KN, 2016, 'Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).', CA, San Francisco, Vol. 34, presented at Genitourinary Cancers Symposium, CA, San Francisco, 07 January 2016 - 09 January 2016,

Conference Papers | 2015

Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015,

Conference Papers | 2015

Abi-Saab T; Bavi P; Jiang J; Siva M; Chadwick D; Joshua A; Roehrl M, 2015, 'The Effect of Time Between Patient Death and Tissue Collection on RNA Integrity of Metastatic Tumors', in MODERN PATHOLOGY, SPRINGERNATURE, pp. 4A - 4A,

Conference Papers | 2015

Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations - A Large Cohort Study', in MODERN PATHOLOGY, SPRINGERNATURE, pp. 510A - 511A,

Conference Papers | 2015

Al-Faraidy N; Deodhare N; Naert K; Joshua A; Hogg D; Butler M; Kamel-Reid S; Alhabeeb A; Ghazarian D, 2015, 'Molecular Profiling of Common Melanoma Mutations A Large Cohort Study', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 510A - 511A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015,

Conference Posters | 2015

Alibhai SMH; Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM, 2015, 'Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2015

Bavi P; Siva M; Buany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MA, Boston, pp. 4A - 4A, presented at 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, MA, Boston, 21 March 2015 - 27 March 2015,

Conference Papers | 2015

Bavi P; Siva M; Butany J; Joshua A; Roehrl M, 2015, 'A Cancer Center's Large-Scale Rapid (Warm) Autopsy Program: Unique Insights Into Tumor Kinetics and Biology', in MODERN PATHOLOGY, SPRINGERNATURE, pp. 4A - 4A,

Conference Papers | 2015

Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Carles J; Mainwaring PN; Evans CP; Parli T; Mansbach HH; Bhattacharya S; Van Os S; Phung D; Tombal BF, 2015, 'Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Posters | 2015

Bruce JP; Danesh A; Winegarden N; Yau P; Virtanen C; Kamel-Reid S; Roehrl MH; Joshua AM; Knox J; Pugh TJ, 2015, 'Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015,

Conference Papers | 2015

Daud A; Joshua AM; Ribas A; Robert C; Hodi FS; Wolchok J; Hwu W-J; Weber JS; Gangadhar TC; Joseph R; Dronca R; Patnaik A; Zarour H; Kefford R; Lindia J; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'A POOLED ANALYSIS OF 655 PATIENTS WITH ADVANCED MELANOMA ENROLLED IN KEYNOTE-001: LONG-TERM EFFICACY OF PEMBROLIZUMAB (MK-3475)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 43 - 43

Conference Presentations | 2015

Daud A; Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph RW; Dronca RS; Patnaik A; Zarour HM; Kefford R; Lindia JA; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Posters | 2015

Gill B; Khoja L; Li ZJ; Hamilton RJ; Koritzinsky M; Penn L; Abdallah K; Pintilie M; Joshua AM, 2015, 'Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.', FL, Orlando, Vol. 33, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015,

Conference Papers | 2015

Hotte SJ; Joshua AM; Torri V; Macfarlane RJ; Basappa NS; Powers J; Winquist E; Mukherjee S; Gregg RW; Kollmannsberger CK; Finch DL; Xu H; Hausman DF; Seymour L; Eisenhauer EA; Chi KN, 2015, 'IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015,

Conference Posters | 2015

Jeganathan S; Zoubeidi A; Gleave M; Wouters BG; Joshua AM, 2015, 'Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015,

Conference Posters | 2015

Joshua AM; Gill B; Khoja L; Pintilie M; Abdallah K, 2015, 'Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Posters | 2015

Khoja I; Joshua AM; Wang L; Hogg D; Linh N; Sotov V; Motta V; Scheid L; Gray D; Hirano N; Butler MO, 2015, 'A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015,

Conference Posters | 2015

Khoja L; Kurtz G; Bernstein M; Joshua AM; Hogg D; Zadeh G; Laperriere N; Menard C; Miller B-A; Kongkham PN; Atenafu EG; Butler MO; Chung C, 2015, 'Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Posters | 2015

Kibiro M; Khoja L; Hogg D; Butler MO; Metser U; Atenafu EG; Joshua AM, 2015, 'Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM)', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015

Conference Papers | 2015

Leibowitz-Amit R; Pintille M; Laird AD; Aftab DT; Berger R; Chi KN; Joshua AM, 2015, 'Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015,

Conference Posters | 2015

McWhirter E; Hamid O; Chmielowski B; Carvajal RD; Jaffray DA; Driscoll B; Shek T; Yeung I; Keller H; McKee TD; Pearce TE; Kroll S; Joshua AM, 2015, 'A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Presentations | 2015

Montgomery B; Joshua A; Gleave M; Fleshner N; Bubley G; True L; Tretiakova M; Wu K; Novotny W; Peterson A; Amelsberg A; Taplin ME, 2015, 'A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer', presented at European Cancer Congress 2015 / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 25 September 2015 - 29 September 2015,

Conference Posters | 2015

Montgomery RB; Antonarakis ES; Hussain M; Fizazi K; Joshua AM; Attard G; Sadar M; Perabo F; Chi KN, 2015, 'A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2015

Puts M; Sattar S; McWatters K; Lee K; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Jang RW-J; Alibhai SMH, 2015, 'A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2015

Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Zarour HM; Kefford R; Loboda A; Albright A; Kang SP; Ebbinghaus S; Yearley J; Murphy E; Nebozhyn M; Lunceford JK; McClanahan T; Ayers M; Daud A, 2015, 'Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2015

Ribas A; Wolchok JD; Robert C; Kefford R; Hamid O; Daud A; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Hodi FS, 2015, 'UPDATED CLINICAL EFFICACY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) IN 411 PATIENTS WITH MELANOMA', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, PEOPLES R CHINA, Shanghai, pp. E24 - E24, presented at 7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research, PEOPLES R CHINA, Shanghai, 10 April 2015 - 12 April 2015,

Conference Papers | 2015

Robert C; Joshua AM; Kefford R; Joseph RW; Wolchok JD; Hodi FS; Hamid O; Weber JS; Gangadhar TC; Dronca RS; Patnaik A; Zarour HM; Hwu W-J; Hersey P; Daud A; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Ribas A, 2015, 'Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Posters | 2015

Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Wouters B; Tannock IF, 2015, 'Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015,

Conference Posters | 2015

Wilson MK; Bedard PL; Joshua AM; Mackay H; Butler MO; Dhani NC; Lheureux S; Martin-Lorente C; Rodriguez-Freixinos V; Clarke B; Shaw P; Milea A; Wang L; Kamel-Reid S; Stockley T; Bruce J; Pugh TJ; Oza AM, 2015, 'Molecular profiling and targeted therapy in advanced endometrial cancer.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2015

Wolchok JD; Hamid O; Ribas A; Robert C; Kefford R; Hwu W-J; Weber JS; Joshua AM; Gangadhar TC; Dronca RS; Daud A; Patnaik A; Joseph RW; Zarour HM; Li XN; Xue D; Ebbinghaus S; Kang SP; Perrone AM; Hodi FS, 2015, 'Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015,

Conference Papers | 2014

Alimohamed NS; Leibowitz-Amit R; Templeton AJ; Seah J-A; Vera-Badillo FE; Joshua AM; Knox JJ; Tannock I; Sridhar SS, 2014, 'Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Armstrong AJ; Tombal B; Sternberg CN; Higano CS; Rathkopf DE; Loriot Y; Saad F; Joshua AM; De Bono JS; Venner PM; Caries J; Mainwaring PN; Evans CP; Noonberg SB; Mansbach HH; Bhattacharya S; Perabo F; Phung D; Beer TM, 2014, 'Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Azad A; Lester R; Leibowitz-Amit R; Joshua AM; Heng DYC; Eigl BJ; Chi KN, 2014, 'Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Azad A; Lester R; Leibowitz-Amit R; Joshua AM; Heng DYC; Eigl BJ; Chi KN, 2014, 'Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Beer TM; Armstrong AJ; Sternberg CN; Higano CS; Iversen P; Loriot Y; Rathkopf DE; Bhattacharya S; Carles J; De Bono JS; Evans CP; Joshua AM; Kim C-S; Kimura G; Mainwaring PN; Mansbach HH; Miller K; Noonberg SB; Venner PM; Tombal B, 2014, 'Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Daud A; Hamid O; Robert C; Hodi FS; Wolchok JD; Hwu WJ; Weber JS; Kefford R; Hersey P; Joshua AM; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Gerigich K; Lunceford J; Emacipator K; Dolled-Filhart M; Li X; Kang P; Ebbinghaus S; Ribas A, 2014, 'Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 48 - 49, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014,

Conference Papers | 2014

Daud AI; Hamid O; Ribas A; Hodi FS; Hwu W-J; Kefford R; Wolchok J; Hersey P; Weber JS; Joseph R; Gangadhar TC; Dronca RS; Patnaik A; Zarour H; Joshua AM; Gergich K; Wu D; Lunceford JK; Emancipator K; Dolled-Filhart M; Li N; Ebbinghaus S; Kang SP; Robert C, 2014, 'Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014,

Conference Papers | 2014

Efstathiou E; Deshpande H; George D; Joshua AM; Taplin M-E; Griffin TW; Londhe A; Todd M; Molina A, 2014, 'An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014,

Conference Papers | 2014

Hamid O; Robert C; Ribas A; Wolchok JD; Hodi FS; Kefford R; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber JS; Joseph RW; Gergich K; Li XN; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-347 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Hamilton RJ; Li J; Naini V; San Kheoh T; De Porre P; Molina A; Lelbowitz-Amit R; De Bono JS; Scher HI; Ryan CJ; Chi KN; Joshua AM, 2014, 'Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Hersey P; Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Weber J; Dronca R; Zarour H; Gergich K; Li X; Iannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'EFFICACY AND SAFETY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY MK-3475 IN 411 PATIENTS (pts) WITH MELANOMA', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 49,

Conference Papers | 2014

Hodi FS; Ribes A; Daud A; Hamid O; Robert C; Kefford R; Hwu W-J; Gangadhar TC; Joshua AM; Hersey P; Weber JS; Dronca RS; Perrone AM; Gammage L; Mille D; Xue D; Kang SP; Chun P; Ebbinghaus S; Wolchok JD, 2014, 'Evaluation of immune-related response criteria (irRC) in patients (pis) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Joseph RW; Elassaiss-Schaap J; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid M; Robert C; Daud A; Hwu W-J; Kefford R; Hersey P; Weber JS; Patnaik A; De Alwis DP; Perrone AM; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC, 2014, 'Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz MC; Berry WR; Mukherjee S; Winquist E; Haas NB; Hasabou N; Dmuchowski C; Perabo F; Hirmand M; Foley MA; Rathkopf DE, 2014, 'Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. 44 - 44, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014,

Conference Papers | 2014

Kefford R; Hamid O; Robert C; Ribas A; Wolchock JD; Hodi FS; Joshua AM; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Weber J; Joseph R; Gergich K; Li X; Chun P; Ebbinghaus S; Kang SP; Daud A, 2014, 'Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma', in BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, SCOTLAND, Edinburgh, pp. E56 - E56, presented at 15th World Congress on Cancers of the Skin, SCOTLAND, Edinburgh, 03 September 2014 - 06 September 2014,

Conference Papers | 2014

Kefford R; Ribas A; Hamid O; Robert C; Daud A; Wolchok JD; Joshua AM; Hodi FS; Gangedher TC; Hersey P; Weber JS; Dronca RS; Patnaik A; Zarour HM; Dolled-Filhart M; Lunceford J; Emancipator K; Ebbinghaus S; Rang SP; Hwu W-J, 2014, 'Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Khoja L; Kurtz G; Zadeh G; Laperriere N; Menard C; Millar B-A; Bernstein M; Kongkham P; Joshua A; Hogg D; Butler M; Chung C, 2014, 'INCREASED ACUTE RADIATION EFFECT (ARE) WITH IPILUMUMAB AND RADIOSURGERY IN PATIENTS WITH MELANOMA BRAIN METASTASES', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC,

Conference Papers | 2014

Leibowitz-Amit R; Atenafu EG; Seah J-A; Templeton AJ; Vera-Badillo FE; Alimohamed NS; Knox JJ; Sridhar SS; Tannock I; Joshua AM, 2014, 'Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Leibowitz-Amit R; Atenafu EG; Seah J-A; Templeton AJ; Vera-Badillo FE; Solow HL; Knox JJ; Sridhar SS; Tannock I; Joshua AM, 2014, 'Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Leibowitz-Amit R; Joshua AM; Ezzat S; Bourdeau I; Olney H; Oosting S; Ruether JD; Chin S; Palmieri C; Seah J-A; Assa SL; Krzyzanowska M; Knox JJ, 2014, 'A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Leibowitz-Amit R; Joshua AM; Ezzat S; Bourdeau I; Olney H; Oosting S; Seah J-A; Ruether JD; Chin S; Asa SL; Krzyzanowska MK; Knox JJ, 2014, 'A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Ribas A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Lannone R; Kang SP; Ebbinghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY,

Conference Papers | 2014

Ribes A; Hodi FS; Kefford R; Hamid O; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Joshua AM; Hersey P; Weber JS; Dronca RS; Zarour HM; Gergich K; Li XN; Iannone R; Kang SP; Ebblnghaus S; Robert C, 2014, 'Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014,

Conference Papers | 2014

Robert C; Joshua AM; Weber JS; Ribas A; Hodi FS; Kefford RF; Daud A; Wolchok JD; Hwu W-J; Gangadhar TC; Patnaik A; Hersey P; Dronca R; Zarour H; Ge Y; Lindia JA; Giannotti M; Ebbinghaus S; Kang SP; Hamid O, 2014, 'PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 39th ESMO Congress (ESMO), SPAIN, Madrid, 26 September 2014 - 30 September 2014,

Conference Papers | 2014

Seah J-A; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Joshua AM; Knox JJ; Sridhar SS, 2014, 'Evaluation of the neutrophil-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) and correlation with pathologic response to treatment', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Seah J-A; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Joshua AM; Knox JJ; Tannock I; Sridhar SS, 2014, 'Neoadjuvant gemcitabine-cisplatin (GC) for muscle-invasive bladder cancer (MIBC): Does midway CT staging predict for pathologic complete response (pCR)?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2014

Tan Q; Joshua A; Saggar JK; Man Y; Lee CCM; Wouters BR; Tannock IF, 2014, 'Pantoprazole enhances the activity of docetaxel chemotherapy for solid tumors by inhibition of autophagy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, CA, San Diego, 26 February 2014 - 01 March 2014,

Conference Papers | 2014

Vera-Badillo FE; Leibowitz-Amit R; Templeton A; Seah J-A; Sridhar SS; Knox JJ; Tannock I; Joshua AM, 2014, 'Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014,

Conference Papers | 2013

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Dal Pra A; Zannella V; Glicksman R; Sykes J; Muaddi H; Joshua AM; Wouters BG; Milosevic M; Koritzinsky M; Bristow RG, 2013, 'Metformin and Prostate Cancer Radiation Therapy: Improved Outcomes Due to Enhanced Tumor Oxygenation', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, GA, Atlanta, pp. S170 - S170, presented at 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), GA, Atlanta, 22 September 2013 - 25 September 2013,

Conference Papers | 2013

Downes MR; Sweet J; Zannella V; Bowes B; Koritzinsky M; Evans AJ; Trachtenberg J; Jewett M; Finelli A; Fleshner N; Pollak M; Joshua AM, 2013, 'The Effects of Metformin on the mTORC Pathway in Prostate Cancer', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MD, Baltimore, pp. 207A - 207A, presented at 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), MD, Baltimore, 02 March 2013 - 08 March 2013,

Conference Papers | 2013

Downes MR; Sweet J; Zannella V; Bowes B; Koritzinsky M; Evans AJ; Trachtenberg J; Jewett M; Finelli A; Fleshner N; Pollak M; Joshua AM, 2013, 'The Effects of Metformin on the mTORC Pathway in Prostate Cancer', in MODERN PATHOLOGY, NATURE PUBLISHING GROUP, MD, Baltimore, pp. 207A - 207A, presented at 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), MD, Baltimore, 02 March 2013 - 08 March 2013,

Conference Papers | 2013

Hotte SJ; Eisenhauer EA; Joshua AM; Kumar V; Ellard S; Gregg RW; Macfarlane RJ; Winquist E; Torri V; Ruether JD; Basappa NS; Kakumanu AS; North SA; Kollmannsberger CK; Tinker A; Mirchandani D; Tassignon A; Hausman DF; Allan AL; Chi KN, 2013, 'NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Joshua AM; Zannella VE; Downes MR; Bowes B; Koritzinsky M; Sweet J; Trachtenberg J; Jewett MAS; Finelli A; Fleshner NE; Pollak MN, 2013, 'Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Leibowitz-Amit R; Templeton AJ; Atenafu EG; Vera-Badillo FE; Chllamma M; Solow HL; Knox JJ; Tannock I; Sridhar SS; Joshua AM, 2013, 'Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM; Tannock I; Alibhai SMH, 2013, 'A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Margel D; Urbach DR; Lipscombe L; Bell C; Kilkarni G; Austin P; Joshua AM; Fleshner NE, 2013, 'Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Ribas A; Robert C; Daud A; Hodi FS; Wolchok JD; Kefford R; Patnaik A; Hwu W-J; Weber JS; Joshua A; Hersey P; Gangadhar TC; Joseph RW; Dronca RS; Zarour HM; Ebbinghaus S; Gergich K; Li XN; Kang SP; Hamid O, 2013, 'Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013,

Conference Papers | 2013

Tan Q; Joshua A; Saggar J; Yu M; Lee CM; Koritzinsky M; Wouters BR; Tannock IF, 2013, 'Pantoprazole enhances the activity of chemotherapy for solid tumors by inhibition of autophagy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 06 April 2013 - 10 April 2013,

Conference Papers | 2013

Templeton A; Wang L; Vera-Badillo F; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore MJ; Sridhar SS; Joshua AM; Tannock I, 2013, 'From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO), FL, Orlando, 14 February 2013 - 16 February 2013,

Conference Papers | 2012

Brade AM; Kim J; Brierley J; Dinniwell R; Wong R; Cho C; Kassam Z; Joshua A; Knox J; Dawson L, 2012, 'Phase I Study of Sorafenib and Whole-liver Radiation Therapy (WLRT) or Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, MA, Boston, pp. S11 - S12, presented at 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), MA, Boston, 28 October 2012 - 31 October 2012,

Conference Papers | 2012

Chi K; Yu EY; Ellard S; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME, 2012, 'A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 297 - 297, presented at 37th Congress of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 28 September 2012 - 02 October 2012,

Conference Papers | 2012

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Kollmannsberger CK; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY,

Conference Papers | 2012

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012,

Conference Papers | 2012

Joshua AM; Evren S; Zannella VE; Bowes B; Fleshner NE; Jewett MAS; Finelli A; Evans A; Koritzinsky M; Sweet J; Pollak MN, 2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012,

Conference Papers | 2012

Joshua AM; Zannella V; Bowes B; Koritzinsky M; Sweet J; Evans A; Trachtenberg J; Jewett M; Finenlli A; Fleshner N; Pollak M, 2012, 'A phase II study of neoadjuvant metformin in prostatic carcinoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH,

Conference Papers | 2012

Montgomery RB; Joshua A; Hannah AL; Peterson AC; Lopez C; Gleave ME; Taplin M-E, 2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012,

Conference Posters | 2011

Dhani N; Emmeneger U; Sridhar S; Knox J; Tannock I; Day J; Manthe J; Groskopf J; Joshua AM, 2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 71,

Conference Posters | 2011

Finelli A; Horgan AM; Evans A; Kim TK; Durrant K; Yap S; Cassol CA; Dubinski W; Fleshner N; Jewett MAS; Joshua AM; Sridhar SS; Zlotta A; Knox JJ, 2011, 'Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)', Vol. 29,

Conference Posters | 2011

Groskopf J; Niraula S; Emmeneger U; Adams L; Tannock I; Sridhar SS; Knox JJ; Day JR; Manthe J; Joshua AM, 2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.', Vol. 29,

Conference Posters | 2011

Joshua AM; Cockburn N; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and inter-tissue heterogeneity and disease progression', Vol. 71,

Conference Papers | 2011

Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn IA, 2011, 'Evaluation of PTEN and TMPRSS2-ERG Abnormalities in Prostate Cancer by FISH and Immunohistochemistry To Address Intra- and Inter-Tissue Heterogeneity and Disease Progression', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, TX, San Antonio, pp. 393A - 393A, presented at 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology, TX, San Antonio, 26 February 2011 - 04 March 2011,

Conference Posters | 2011

Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn IA, 2011, 'Evaluation of PTEN and TMPRSS2-ERG Abnormalities in Prostate Cancer by FISH and Immunohistochemistry To Address Intra- and Inter-Tissue Heterogeneity and Disease Progression', TX, San Antonio, Vol. 24, pp. 393A - 393A, presented at 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology, TX, San Antonio, 26 February 2011 - 04 March 2011,

Conference Posters | 2011

Joshua AM; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and intertissue heterogeneity and disease progression.', Vol. 29,

Conference Posters | 2011

Niraula S; Emmeneger U; Adams L; Tannock I; Sridhar SS; Knox JJ; Day JR; Manthe J; Groskopf J; Joshua AM, 2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 29,

Conference Papers | 2011

Tan Q; Patel K; Lee CM; Zhang J; Joshua A; Koritzinsky M; Wouters BG; Tannock IF, 2011, 'Mechanisms by which pantoprazole, a proton pump inhibitor, enhances the activity of doxorubicin in solid tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH,

Conference Abstracts | 2010

Buckman RA; Berman HK; Sridhar SS; Joshua AM, 2010, 'How much do the side effects of chemotherapy matter? Patients' attitudes to side effects versus a potential loss of duration of remission', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 28,

Conference Posters | 2010

Fahim L; Cockburn N; Joshua A; Warde P; Sweet J, 2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 23, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DC, Washington, 20 March 2010 - 26 March 2010,

Conference Posters | 2010

Fahim L; Cockburn N; Joshua A; Warde P; Sweet J, 2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 90, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DC, Washington, 20 March 2010 - 26 March 2010,

Conference Posters | 2010

Niraula S; Tannock I; Pond GR; De Wit R; Eisenberger MA; Joshua AM, 2010, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.', Vol. 28,

Conference Posters | 2009

Joshua A; Marrano P; Yoshimoto M; Evans A; Van der Kwast T; Zielenska M; Squire J, 2009, 'Correlations between telomere dysfunction and genomic instability in prostatic carcinogenesis', Vol. 69,

Conference Posters | 2008

Joshua AM; Broom R; Milosevic M; Jewett M; Evans A; Asa S; Tannock IF; Knox JJ, 2008, 'Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP)', Vol. 26,

Conference Posters | 2007

Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley JR; Evans AJ; Squire JA, 2007, 'Telomere length analysis of high-grade prostatic intraepithelial neoplasia (HPIN) and adjacent stroma predicts outcome in prostate cancer and provides evidence of field carcinogenesis', CA, San Diego, Vol. 20, pp. 154A - 154A, presented at 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, CA, San Diego, 24 March 2007 - 30 March 2007,

Conference Posters | 2006

Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 19, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006,

Conference Posters | 2006

Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 86, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006,

Conference Posters | 2006

Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis.', GA, Atlanta, Vol. 24, pp. 546S - 546S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006,

Conference Posters | 2006

Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2/ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer.', GA, Atlanta, Vol. 24, pp. 548S - 548S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006,

Conference Posters | 2005

Joshua AM; Nordman I; Venkatawaran R; Stockler M; Boyer M; Clarke S, 2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC).', FL, Orlando, Vol. 23, pp. 431S - 431S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005,

Prostate Cancer, Melanoma, Immuno-Oncology, Metabolomics, Autophagy, Cholesterol Metabolism

51�Թ�app

Follow

Associate Professor Anthony Joshua

Follow me